Skip to main content

RADIOGENOMICA PARA LA PREDICCION DEL CANCER DE PROSTATA AGRESIVO MEDIANTE INTELIGENCIA ARTIFICIAL.

PI20/01666

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Execution centre INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO VALLE DE HEBRON (VHIR)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 58
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Validation of the Barcelona-MRI predictive model when PI-RADS v2.1 is used with transperineal prostate biopsies

  • Morote Robles, Juan|||0000-0002-2168-323X
  • Paesano, Nahuel|||0000-0001-9278-5543
  • Picola, Natàlia|||0000-0002-8944-4294
  • Muñoz Rodríguez, José Manuel|||0000-0002-4688-6420
  • Ruiz-Plazas, Xavier|||0000-0003-2135-3860
  • Muñoz Rivero, Marta Viridiana|||0000-0002-6899-3956
  • Celma, Ana|||0000-0002-3128-3811
  • García-de Manuel, Gemma
  • Miró, Berta|||0000-0001-6049-8697
  • Servian, Pol|||0000-0002-3727-8159
  • Abascal, Jose Maria|||0000-0001-8374-6593
To validate the Barcelona magnetic resonance imaging predictive model (BCN-MRI PM) in men with pre-biopsy multiparametric MRI (mpMRI) reported with the Prostate Imaging Reporting and Data System (PI-RADS) v2.1, followed by transrectal and transperineal prostate biopsies. Prospective analysis of 3,264 men with PSA.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Role of Digital Rectal Examination for Early Detection of Significant Prostate Cancer in the Era of Magnetic Resonance Imaging

  • Morote Robles, Juan|||0000-0002-2168-323X
  • Paesano, Nahuel|||0000-0001-9278-5543
  • Picola, Natàlia|||0000-0002-8944-4294
  • Muñoz Rodríguez, José Manuel|||0000-0002-4688-6420
  • Ruiz-Plazas, Xavier|||0000-0003-2135-3860
  • Muñoz Rivero, Marta Viridiana|||0000-0002-6899-3956
  • Celma, Ana|||0000-0002-3128-3811
  • García-de Manuel, Gemma
  • Miró, Berta|||0000-0001-6049-8697
  • Abascal, Jose Maria|||0000-0001-8374-6593
  • Servian, Pol|||0000-0002-3727-8159
  • Méndez Fernández, Olga|||0000-0003-4237-330X
  • Trilla Herrera, Enrique|||0000-0001-9401-0872
The role of digital rectal examination (DRE) in the early detection of significant prostate cancer (PCa) is being questioned in the era of magnetic resonance imaging (MRI). However, some men with suspected PCa may still be identified solely through DRE, even with low serum prostate-specific antigen (PSA) levels. Additionally, most predictive models designed to improve significant PCa diagnostic pathways incorporate DRE findings. We assessed the role of DRE among 5005 men with serum PSA levels.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Investigating Efficient Risk-Stratified Pathways for the Early Detection of Clinically Significant Prostate Cancer

  • Morote Robles, Juan|||0000-0002-2168-323X
  • Borque-Fernando, Ángel|||0000-0003-0178-4567
  • Esteban, Luis M.|||0000-0002-3007-302X
  • Celma, Ana|||0000-0002-3128-3811
  • Campistol i Torres, Miriam|||0000-0002-3212-3473
  • Miró, Berta|||0000-0001-6049-8697
  • Méndez Fernández, Olga|||0000-0003-4237-330X
  • Trilla Herrera, Enrique|||0000-0001-9401-0872
Risk-stratified pathways (RSPs) are recommended by the European Association of Uro-logy (EAU) to improve the early detection of clinically significant prostate cancer (csPCa). RSPs can reduce magnetic resonance imaging (MRI) demand, prostate biopsies, and the over-detection of insignificant PCa (iPCa). Our goal is to analyze the efficacy and cost-effectiveness of several RSPs by using sequential stratifications from the serum prostate-specific antigen level and digital rectal examination, the Barcelona risk calculators (BCN-RCs), MRI, and Proclarix™. In a cohort of 567 men with a serum PSA level above 3.0 ng/mL who underwent multiparametric MRI (mpMRI) and targeted and/or systematic biopsies, the risk of csPCa was retrospectively assessed using Proclarix™ and BCN-RCs 1 and 2. Six RSPs were compared with those recommended by the EAU that, stratifying men from MRI, avoided 16.7% of prostate biopsies with a prostate imaging-reporting and data system score of <3, with 2.6% of csPCa cases remaining undetected. The most effective RSP avoided mpMRI exams in men with a serum PSA level of.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Analysis of Inflammatory Features in Suspicious Lesions for Significant Prostate Cancer on Magnetic Resonance Imaging-Are They Mimickers of Prostate Cancer?

  • Morote Robles, Juan|||0000-0002-2168-323X
  • Celma, Ana|||0000-0002-3128-3811
  • Semidey, M. Eugenia
  • Antolín, Andreu|||0000-0001-6973-4246
  • Miró, Berta|||0000-0001-6049-8697
  • Méndez Fernández, Olga|||0000-0003-4237-330X
  • Trilla Herrera, Enrique|||0000-0001-9401-0872
Background. Inflammatory features can mimic PCa in suspicious MRI-lesions. Objectives: To assess the incidence of inflammatory features in targeted biopsies to suspicious lesions. Methods. A prospective analysis was conducted of 531 MRI-suspicious lesions with Prostate Imaging-Reporting and Data System (PI-RADS) scores of 3 to 5 in 364 men suspected of having PCa. Results. The incidence of inflammatory features in the MRI-suspicious lesions without PCa was 69.6%, compared to 48.1% in those with PCa (p < 0.001). Among the suspicious lesions without PCa, the incidence of inflammatory features ranged from 68.6% to 71.2% across the PI-RADS categories (p = 0.870). Mild chronic prostatitis increased with higher PI-RADS scores, while acute prostatitis decreased, and granulomatous prostatitis was exclusively observed in patients with PI-RADS scores of 4 and 5. The incidence of inflammatory features in the lesions with insignificant PCa (grade group 1) was 66.7%, compared to 42.7% in those with significant PCa (grade group 2 to 5; p = 0.027). The detection of inflammatory features in MRI-suspicious lesions was identified as an independent predictor of a lower likelihood of significant PCa detection, with an odds ratio (OR) of 0.326 (95% CI 0.196-0.541). Mild chronic prostatitis was the only type of prostatitis which was an independent predictor of a lower likelihood of significant PCa, with an OR of 0.398 (95% CI 0.268-0.590). Conclusions. These data suggest that inflammatory features may be considered mimickers of significant PCa on MRI.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Validation of the Barcelona Magnetic Resonance Imaging Predictive Model for Significant Prostate Cancer Detection in Men Undergoing Mapping per 0.5 Mm-Core Targeted Biopsies of Suspicious Lesions and Perilesional Areas

  • Paesano, Nahuel|||0000-0001-9278-5543
  • Català, Violeta
  • Tcholakian, Larisa
  • Alomar Serrallach, Xavier
  • Barranco, Miguel Ángel
  • Hernández Mancera, Jonathan|||0000-0002-2267-7536
  • Miró, Berta|||0000-0001-6049-8697
  • Trilla Herrera, Enrique|||0000-0001-9401-0872
  • Morote Robles, Juan|||0000-0002-2168-323X
The validation of predictive models is essential for informing clinical decisions, particularly in new individual populations or as diagnostic methods advance. This study evaluates the performance of the Barcelona-MRI predictive model (BCN-MRI PM) for identifying significant prostate cancer (sPCa) within the context of an advanced prostate biopsy protocol. In a cohort of 457 men suspected of having PCa, the model demonstrated high accuracy and clinical applicability, reducing unnece-ssary biopsies by 24.9% while maintaining a 95% detection rate for sPCa. These results validate the efficacy of the BCN-MRI PM and support its readiness for clinical implementation in this diagnostic framework. Background/Objectives: Validation of predictive models (PMs) is crucial to be implemented in new populations or when advances in diagnostic approaches occurred. The aim of this study is to validate the BCN-MRI PM for sPCa when a highly effective prostate biopsy protocol is used. Methods: A prospective cohort of 457 men suspected of having PCa, for whom MRI results were reported with the Prostate Imaging-Reporting and Data System (PI-RADS) v 2.1, underwent a per 0.5 mm-core mapping targeted biopsy of suspicious lesions and perilesional areas, followed by a 12-core-systematic biopsy. These procedures took place between 1 February 2022, and 29 February 2024, at a reference center for prostate biopsy. The individual likelihood of sPCa was assessed through the BCN-MRI risk calculator. Results: The overall sPCa detection rate was 58.3%. The calibration curve of the BCN-MRI PM showed an appropriate accuracy between expected and observed probabilities with a discrimination ability for sPCa yielding an area under the curve (AUC) of 0.862 (95% CI 0.828-0.896) comparable to the AUC of 0.858 (95% CI 0.833-0.883) observed in the development cohort. The application of the BCN-MRI PM provided a net benefit over performing biopsies on all men, avoiding 24.9% of prostate biopsies at 95% sensitivity for sPCa, compared to the 23.7% reduction observed in the development cohort. Conclusions: We conclude that the BCN-MRI PM is ready to be implemented when this biopsy protocol is employed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sequencing the Barcelona-MRI predictive model and Proclarix for improving the uncertain PI-RADS 3

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Developing a Predictive Model for Significant Prostate Cancer Detection in Prostatic Biopsies from Seven Clinical Variables, Is Machine Learning Superior to Logistic Regression?

  • Morote Robles, Juan|||0000-0002-2168-323X
  • Miró, Berta|||0000-0001-6049-8697
  • Hernando-Sánchez, Patricia
  • Paesano, Nahuel|||0000-0001-9278-5543
  • Picola, Natàlia|||0000-0002-8944-4294
  • Muñoz Rodríguez, Jesús|||0000-0001-5406-4729
  • Ruiz-Plazas, Xavier|||0000-0003-2135-3860
  • Muñoz Rivero, Marta Viridiana|||0000-0002-6899-3956
  • Celma, Ana|||0000-0002-3128-3811
  • García-de Manuel, Gemma
  • Servian, Pol|||0000-0002-3727-8159
  • Abascal, Jose Maria|||0000-0001-8374-6593
  • Trilla Herrera, Enrique|||0000-0001-9401-0872
  • Méndez Fernández, Olga|||0000-0003-4237-330X
Objective: This study compares machine learning (ML) and logistic regression (LR) algorithms in developing a predictive model for sPCa using the seven predictive variables from the Barcelona (BCN-MRI) predictive model. Method: A cohort of 5005 men suspected of having PCa who underwent MRI and targeted and/or systematic biopsies was used for training, testing, and validation. A feedforward neural network (FNN)-based SimpleNet model (GMV) and a logistic regression-based model (BCN) were developed. The models were evaluated for discrimination ability, precision-recall, net benefit, and clinical utility. Both models demonstrated strong predictive performance. Results: The GMV model achieved an area under the curve of 0.88 in training and 0.85 in test cohorts (95% CI: 0.83-0.90), while the BCN model reached 0.85 and 0.84 (95% CI: 0.82-0.87), respectively (p.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efficacy of Prostate Biopsies via Transperineal and Transrectal Routes for Significant Prostate Cancer Detection, A Multicenter Paired-Matched Study

  • Paesano, Nahuel|||0000-0001-9278-5543
  • Picola, Natàlia|||0000-0002-8944-4294
  • Muñoz Rodríguez, Jesús|||0000-0001-5406-4729
  • Ruiz-Plazas, Xavier|||0000-0003-2135-3860
  • Muñoz Rivero, Marta Viridiana|||0000-0002-6899-3956
  • Celma, Ana|||0000-0002-3128-3811
  • García-de Manuel, Gemma
  • Miró, Berta|||0000-0001-6049-8697
  • Servian, Pol|||0000-0002-3727-8159
  • Abascal, Jose Maria|||0000-0001-8374-6593
  • Trilla Herrera, Enrique|||0000-0001-9401-0872
  • Morote Robles, Juan|||0000-0002-2168-323X
Background: A transperineal approach to prostate biopsy is now recommended to reduce the risk of infectious complications associated with the transrectal route. Our aim is to compare the efficacy of transrectal- and transperineal-guided biopsies involving the magnetic resonance imaging (MRI) of index lesions in detecting significant prostate cancer (sPCas), and to evaluate the role of systematic biopsies. Methods: In a prospective and multicenter trial conducted in an opportunistic early detection program for sPCa in Catalonia (Spain), between 2021 and 2023, 4029 men suspected of having PCa underwent multiparametric MRI followed by guided and systematic biopsies. From this cohort, we retrospectively selected 1376 men with reports of the size and localization of their index lesions. A matched group of 325 pairs of men subjected to transrectal and transperineal biopsy were chosen to account for confounding variables. We compared sPCa detection rates determined via index lesions and systematic biopsies, as well as by lesion localization. Results: Transperineal and transrectal biopsies detected sPCa in 49.5% vs. 40.6% overall (p = 0.027), 44.6% vs. 30.8% from index lesions (p = 0.001), and 24.3% vs. 35.1% from systematic biopsies (p = 0.003). SPCa detection rates were higher in transperineal biopsies across all index lesion localizations, with significant increases in the anterior zone (47.8% vs. 20.8% at the mid-base, p = 0.039, and 52.9% vs. 24.2% at the apex, p = 0.024) and central zone (33.3% vs. 5.9%, p = 0.003). With regards to SPCa detected only in systematic biopsies, 10.5% of cases were detected in transrectal biopsies and 4.9% of cases were detected in transperineal biopsies (p = 0.012). Conclusions: Targeted biopsies conducted via the transperineal route showed higher sPCa detection rates than transrectal biopsies, particularly for anterior and apical lesions, with systematic biopsies showing reduced utility.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Who with suspected prostate cancer can benefit from Proclarix after multiparametric magnetic resonance imaging?

  • Morote Robles, Joan
  • Regis Plácido, Lucas
  • Celma Domènech, Ana
  • Torres Ramirez, Inés de
  • Roche, Sarai
  • Mast, Richard
  • Planas Morin, Jacques
  • Trilla Herrera, Enric
  • Campistol, Miriam
  • Semidey Raven, Maria Eugenia
  • Santamaria Margalef, Anna
Cathepsin D; Magnetic resonance imaging; Proclarix, Catepsina D; Imatges per ressonància magnètica; Proclarix, Catepsina D; Imágenes por resonancia magnética; Proclarix, Proclarix is a new blood-based test to assess the likelihood of clinically significant prostate cancer (csPCa) defined as >2 grade group. In this study, we analyzed whether Proclarix and PSA density (PSAD) could improve the selection of candidates for prostate biopsy after multiparametric magnetic resonance imaging (mpMRI). Proclarix and PSAD were assessed in 567 consecutive men with suspected PCa in whom pre-biopsy 3 Tesla mpMRI, scoring with Prostate Imaging-Report and Data System (PI-RADS) v.2, and guided and/or systematic biopsies were performed. Proclarix and PSAD thresholds having csPCa sensitivity over 90% were found at 10% and 0.07 ng/(mL*cm3), respectively. Among 100 men with negative mpMRI (PI-RADS <3), csPCa was detected in 6 cases, which would have been undetected if systematic biopsies were avoided. However, Proclarix suggested performing a biopsy on 70% of men with negative mpMRI. In contrast, PSAD only detected 50% of csPCa and required 71% of prostate biopsies. In 169 men with PI-RADS 3, Proclarix avoided 21.3% of prostate biopsies and detected all 25 cases of csPCa, while PSAD avoided 26.3% of biopsies, but missed 16% of csPCa. In 190 men with PI-RADS 4 and 108 with PI-RADS 5, Proclarix avoided 12.1% and 5.6% of prostate biopsies, but missed 4.8% and 1% of csPCa, respectively. PSAD avoided 18.4% and 9.3% of biopsies, but missed 11.4% and 4.2% csPCa, respectively. We conclude that Proclarix outperformed PSAD in the selection of candidates for prostate biopsy, especially in men with PI-RADS <3., The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Instituto de Salud Carlos III, (grant number PI20/01666).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Comparing Two Targeted Biopsy Schemes for Detecting Clinically Significant Prostate Cancer in Magnetic Resonance Index Lesions: Two- to Four-Core versus Saturated Transperineal Targeted Biopsy

  • Mendez Fernández, Olga
  • Paesano, Nahuel
  • Picola Brau, Natalia
  • Miro, Berta
  • Abascal, Jose Maria
  • Servian, Pol
  • Enrique, Trilla Herrera
  • Morote Robles, Juan
Number of cores; Prostate cancer; Targeted biopsy, Número de núcleos; Cáncer de próstata; Biopsia dirigida, Nombre de nuclis; Càncer de pròstata; Biòpsia dirigida, Since the optimal scheme for targeted biopsies of magnetic resonance imaging (MRI) suspicious lesions remains unclear, we compare the efficacy of two schemes for these index lesions. A prospective trial was conducted in 1161 men with Prostate Imaging Reporting and Data System v 2.1 3–5 undergoing targeted and 12-core systematic biopsy in four centers between 2021 and 2023. Two- to four-core MRI-transrectal ultrasound fusion-targeted biopsies via the transperineal route were conducted in 900 men in three centers, while a mapping per 0.5 mm core method (saturated scheme) was employed in 261 men biopsied in another center. A propensity-matched 261 paired cases were selected for avoiding confounders other than the targeted biopsy scheme. CsPCa (grade group ≥ 2) was identified in 125 index lesions (41.1%) when the two- to four-core scheme was employed, while in 187 (71.9%) when the saturated biopsy (p < 0.001) was used. Insignificant PCa (iPCa) was detected in 18 and 11.1%, respectively (p = 0.019). Rates of csPCa and iPCa remained similar in systematic biopsies. CsPCa detected only in systematic biopsies were 5 and 1.5%, respectively (p = 0.035) in each group. The saturated scheme for targeted biopsies detected more csPCa and less iPCa than did the two- to four-core scheme in the index lesions. The rate of csPCa detected only in the systematic biopsies decreased when the saturated scheme was employed., This research was funded by the Ministerio de Asuntos Económicos y Transformación Digital (SP) (MIA.2021.M02.0005) and the Instituto de Salut Carlos III (SP) (PI20/01666).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Magnetic Resonance Imaging-Based Predictive Models for Clinically Significant Prostate Cancer: A Systematic Review

  • Celma Domènech, Ana
  • Regis Plácido, Lucas
  • Planas Morin, Jacques
  • Trilla Herrera, Enric
  • Morote Robles, Joan
  • Triquell Llauradó, Marina
  • Campistol, Miriam
  • Cuadras Solé, Mercè
Magnetic resonance imaging; Predictive model; Prostate cancer, Imatges per ressonància magnètica; Model predictiu; Càncer de pròstata, Imágenes por resonancia magnética; Modelo predictivo; Cáncer de próstata, MRI can identify suspicious lesions, providing the semi-quantitative risk of csPCa through the Prostate Imaging-Report and Data System (PI-RADS). Predictive models of clinical variables that individualise the risk of csPCa have been developed by adding PI-RADS score (MRI-PMs). Our objective is to analyse the current developed MRI-PMs and define their clinical usefulness. A systematic review was performed after a literature search performed by two independent investigators in PubMed, Cochrane, and Web of Science databases, with the Medical Subjects Headings (MESH): predictive model, nomogram, risk model, magnetic resonance imaging, PI-RADS, prostate cancer, and prostate biopsy. This review was made following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) criteria and studied eligibility based on the Participants, Intervention, Comparator, and Outcomes (PICO) strategy. Among 723 initial identified registers, 18 studies were finally selected. Warp analysis of selected studies was performed with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. Clinical predictors in addition to the PI-RADS score in developed MRI-PMs were age, PCa family history, digital rectal examination, biopsy status (initial vs. repeat), ethnicity, serum PSA, prostate volume measured by MRI, or calculated PSA density. All MRI-PMs improved the prediction of csPCa made by clinical predictors or imaging alone and achieved most areas under the curve between 0.78 and 0.92. Among 18 developed MRI-PMs, 7 had any external validation, and two RCs were available. The updated PI-RADS version 2 was exclusively used in 11 MRI-PMs. The performance of MRI-PMs according to PI-RADS was only analysed in a single study. We conclude that MRI-PMs improve the selection of candidates for prostate biopsy beyond the PI-RADS category. However, few developed MRI-PMs meet the appropriate requirements in routine clinical practice., This research was funded by the Instituto de Salud Carlos III (ESP), grant number PI20/01666.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A Clinically Significant Prostate Cancer Predictive Model Using Digital Rectal Examination Prostate Volume Category to Stratify Initial Prostate Cancer Suspicion and Reduce Magnetic Resonance Imaging Demand

  • Morote Robles, Joan
  • Celma Domènech, Ana
  • Regis Plácido, Lucas
  • Planas Morin, Jacques
  • Mendez Fernández, Olga
  • Trilla Herrera, Enric
  • Triquell Llauradó, Marina
  • Borque Fernando, Ángel
  • Campistol, Miriam
Magnetic resonance imaging; Predictive model; Prostate cancer, Imágenes por resonancia magnética; Modelo predictivo; Cáncer de próstata, Imatges per ressonància magnètica; Model predictiu; Càncer de pròstata, A predictive model including age, PCa family history, biopsy status (initial vs repeat), DRE (normal vs abnormal), serum prostate-specific antigen (PSA), and DRE prostate volume ca-tegory was developed to stratify initial PCa suspicion in 1486 men with PSA > 3 ng/mL and/or abnormal DRE, in whom mpMRI followed; 2- to 4-core TRUS-guided biopsies where Prostate Imaging Report and Data System (PI-RADS) > 3 lesions and/or 12-core TRUS systematic biopsies were performed in one academic institution between 1 January 2016–31 December 2019. The csPCa detection rate, defined as International Society of Uro-Pathology grade group 2 or higher, was 36.9%. An external validation of designed BCN-RC 1 was carried out on 946 men from two other institutions in the same metropolitan area, using the same criteria of PCa suspicion and diagnostic approach, yielded a csPCa detection rate of 40.8%. The areas under the receiver operating characteristic curves of BCN-RC 1 were 0.823 (95% CI: 0.800–0.846) in the development cohort and 0.837 (95% CI: 0.811–0.863) in the validation cohort (p = 0.447). In both cohorts, BCN-RC 1 exhibited net benefit over performing mpMRI in all men from 8 and 12% risk thresholds, respectively. At 0.95 sensitivity of csPCa, the specificities of BCN-RC 1 were 0.24 (95% CI: 0.22–0.26) in the development cohort and 0.34 (95% CI: 0.31–0.37) in the validation cohort (p < 0.001). The percentages of avoided mpMRI scans were 17.2% in the development cohort and 22.3% in the validation cohort, missing between 1.8% and 2% of csPCa among men at risk of PCa. In summary, BCN-RC 1 can stratify initial PCa suspicion, reducing the demand of mpMRI, with an acceptable loss of csPCa., This research was funded by Instituto de Salut Carlos III (SP) and European Union, grant number PI20/01666.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Efficacy of Prostate Biopsies via Transperineal and Transrectal Routes for Significant Prostate Cancer Detection: A Multicenter Paired–Matched Study

  • Paesano, Nahuel
  • Picola Brau, Natalia
  • Muñoz-Rodriguez, Jesus
  • Ruiz Plazas, Xavier
  • Muñoz Rivero, Marta Viridiana
  • Celma, Ana
  • Miro, Berta
  • Enrique, Trilla Herrera
  • Morote Robles, Juan
Prostate biopsy; Prostate cancer; Transperineal, Biòpsia de pròstata; Càncer de pròstata; Transperineal, Biopsia de próstata; Cáncer de próstata; Transperineal, Background: A transperineal approach to prostate biopsy is now recommended to reduce the risk of infectious complications associated with the transrectal route. Our aim is to compare the efficacy of transrectal- and transperineal-guided biopsies involving the magnetic resonance imaging (MRI) of index lesions in detecting significant prostate cancer (sPCas), and to evaluate the role of systematic biopsies. Methods: In a prospective and multicenter trial conducted in an opportunistic early detection program for sPCa in Catalonia (Spain), between 2021 and 2023, 4029 men suspected of having PCa underwent multiparametric MRI followed by guided and systematic biopsies. From this cohort, we retrospectively selected 1376 men with reports of the size and localization of their index lesions. A matched group of 325 pairs of men subjected to transrectal and transperineal biopsy were chosen to account for confounding variables. We compared sPCa detection rates determined via index lesions and systematic biopsies, as well as by lesion localization. Results: Transperineal and transrectal biopsies detected sPCa in 49.5% vs. 40.6% overall (p = 0.027), 44.6% vs. 30.8% from index lesions (p = 0.001), and 24.3% vs. 35.1% from systematic biopsies (p = 0.003). SPCa detection rates were higher in transperineal biopsies across all index lesion localizations, with significant increases in the anterior zone (47.8% vs. 20.8% at the mid-base, p = 0.039, and 52.9% vs. 24.2% at the apex, p = 0.024) and central zone (33.3% vs. 5.9%, p = 0.003). With regards to SPCa detected only in systematic biopsies, 10.5% of cases were detected in transrectal biopsies and 4.9% of cases were detected in transperineal biopsies (p = 0.012). Conclusions: Targeted biopsies conducted via the transperineal route showed higher sPCa detection rates than transrectal biopsies, particularly for anterior and apical lesions, with systematic biopsies showing reduced utility., This research was supported by the Instituto de Salut Carlos III (SP) and the European Union (PI20/01666).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Multiparametric Magnetic Resonance Imaging Grades the Aggressiveness of Prostate Cancer

  • Morote Robles, Joan
  • Celma Domènech, Ana
  • Regis Plácido, Lucas
  • Mast, Richard
  • Torres Ramirez, Inés de
  • Planas Morin, Jacques
  • Esteban, Luis M.
  • Trilla Herrera, Enric
  • Triquell Llauradó, Marina
  • Borque Fernando, Ángel
  • Semidey Raven, Maria Eugenia
  • Santamaria Margalef, Anna
Aggressiveness; Magnetic resonance imaging; Prostate cancer, Agresividad; Imágenes por resonancia magnética; Cáncer de próstata, Agressivitat; Imatges per ressonància magnètica; Càncer de pròstata, We sought to find further evidence showing the increase in PCa aggressiveness as PI-RADS score increases from four surrogates of PCa aggressiveness: i. prostate biopsy GG (≤3 vs. >3), ii. type of pathology in surgical specimens (favourable vs. unfavourable), iii. clinical stage (localised vs. advanced), and risk of recurrence of localised PCa after primary treatment (low-intermediate vs. high). A group of 692 PCa patients were diagnosed after 3-T multiparametric MRI (mpMRI) and guided and/or systematic biopsies, showing csPCa (GG ≥ 2) in 547 patients (79%) and insignificant PCa (iPCa) in 145 (21%). The csPCa rate increased from 32.4% in PI-RADS < 3 to 95.5% in PI-RADS 5 (p < 0.001). GG ≥ 3 was observed in 7.6% of PCa with PI-RADS < 3 and 32.6% in those with PI-RADS > 3 (p < 0.001). Unfavourable pathology was observed in 38.9% of PCa with PI-RAD < 3 and 68.3% in those with PI-RADS > 3 (p = 0.030). Advanced disease was not observed in PCa with PI-RADS ≤ 3, while it existed in 12.7% of those with PI-RADS > 3 (p < 0.001). High-risk recurrence localised PCa was observed in 9.5% of PCa with PI-RADS < 3 and 35% in those with PI-RADS > 3 (p = 0.001). The PI-RADS score was an independent predictor of all surrogates of PCa aggressiveness as PSA density. We confirmed that mpMRI grades PCa aggressiveness., This research was funded by Instituto de Salut Carlos III (ES) grant number PI20/01666.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and Prostate Cancer Detection

  • Celma Domènech, Ana
  • Picola Brau, Natalia
  • Paesano, Nahuel
  • Ruiz Plazas, Xavier
  • Miro, Berta
  • Muñoz-Rodriguez, Jesus
  • Muñoz Rivero, Marta Viridiana
  • Morote Robles, Juan
Biopsy; Prostate cancer; Screening, Biòpsia; Càncer de pròstata; Cribratge, Biopsia; Cáncer de próstata; Cribado, Concerns exist regarding the effects of 5-alpha reductase inhibitors (5-ARIs) on multipa-rametric magnetic resonance imaging (mpMRI) and clinically significant prostate cancer (csPCa) detection. Our objective is to analyze the effect of 5-ARI on the prostate imaging–reporting and data system (PI-RADS) distribution and csPCa and insignificant PCa (iPCa) detection. Among 2212 men with serum prostate-specific antigen levels of >3.0 ng/mL and/or suspicious digital rectal examinations who underwent mpMRI and targeted and/or systematic biopsies, 120 individuals exposed to 5-ARI treatment for over a year were identified. CsPCa was defined when the grade group (GG) was >2. The overall csPCa and iPCa detection rates were 44.6% and 18.8%, respectively. Since logistic regression revealed independent predictors of PCa, a randomized matched group of 236 individuals was selected for analysis. The PI-RADS distribution was comparable with 5-ARI exposure (p 0.685). The CsPCa detection rates in 5-ARI-naïve men and 5-ARI-exposed men were 52.6% and 47.4%, respectively (p 0.596). IPCa was detected in 37.6 and 62.5%, respectively (p 0.089). The tumor GG distribution based on 5-ARI exposure was similar (p 0.149) to the rates of csPCa and iPCa across the PI-RADS categories. We conclude that exposure to 5-ARI in suspected PCa men did not change the PI-RADS distribution and the csPCa and iPCa detection rates., This research was funded by the Instituto de Salut Carlos III (SP) and the European Union (PI20/01666).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Investigating Efficient Risk-Stratified Pathways for the Early Detection of Clinically Significant Prostate Cancer

  • Esteban, Luis M.
  • Mendez Fernández, Olga
  • Borque Fernando, Ángel
  • Campistol, Miriam
  • Miro, Berta
  • Enrique, Trilla Herrera
  • Celma, Ana
  • Morote Robles, Juan
Prostate cancer; Risk-stratified pathway; Screening, Càncer de pròstata; Via estratificada de risc; Cribratge, Cáncer de próstata; Vía estratificada del riesgo; Cribado, Risk-stratified pathways (RSPs) are recommended by the European Association of Uro-logy (EAU) to improve the early detection of clinically significant prostate cancer (csPCa). RSPs can reduce magnetic resonance imaging (MRI) demand, prostate biopsies, and the over-detection of insignificant PCa (iPCa). Our goal is to analyze the efficacy and cost-effectiveness of several RSPs by using sequential stratifications from the serum prostate-specific antigen level and digital rectal examination, the Barcelona risk calculators (BCN-RCs), MRI, and Proclarix™. In a cohort of 567 men with a serum PSA level above 3.0 ng/mL who underwent multiparametric MRI (mpMRI) and targeted and/or systematic biopsies, the risk of csPCa was retrospectively assessed using Proclarix™ and BCN-RCs 1 and 2. Six RSPs were compared with those recommended by the EAU that, stratifying men from MRI, avoided 16.7% of prostate biopsies with a prostate imaging–reporting and data system score of <3, with 2.6% of csPCa cases remaining undetected. The most effective RSP avoided mpMRI exams in men with a serum PSA level of >10 ng/mL and suspicious DRE, following stratifications from BCN-RC 1, mpMRI, and Proclarix™. The demand for mpMRI decreased by 19.9%, prostate biopsies by 19.8%, and over-detection of iPCa by 22.7%, while 2.6% of csPCa remained undetected as in the recommended RSP. Cost-effectiveness remained when the Proclarix™ price was assumed to be below EUR 200., This research was funded by the Instituto de Salut Carlos III and the European Union, grant number PI20/01666.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy

  • Morote Robles, Joan
  • Celma Domènech, Ana
  • Regis Plácido, Lucas
  • Mast, Richard
  • Torres Ramirez, Inés de
  • Planas Morin, Jacques
  • Trilla Herrera, Enric
  • Triquell Llauradó, Marina
  • Borque Fernando, Ángel
  • Semidey Raven, Maria Eugenia
  • Santamaria Margalef, Anna
Clinically significant prostate cancer; Predictive model; Prostate-specific antigen, Càncer de pròstata clínicament significatiu; Model predictiu; Antigen específic de la pròstata, Cáncer de próstata clínicamente significativo; Modelo predictivo; Antígeno específico de la próstata, This study is a head-to-head comparison between mPSAD and MRI-PMbdex. The MRI-PMbdex was created from 2432 men with suspected PCa; this cohort comprised the development and external validation cohorts of the Barcelona MRI predictive model. Pre-biopsy 3-Tesla multiparametric MRI (mpMRI) and 2 to 4-core transrectal ultrasound (TRUS)-guided biopsies for suspicious lesions and/or 12-core TRUS systematic biopsies were scheduled. Clinically significant PCa (csPCa), defined as Gleason-based Grade Group 2 or higher, was detected in 934 men (38.4%). The area under the curve was 0.893 (95% confidence interval [CI]: 0.880–0.906) for MRI-PMbdex and 0.764 (95% CI: 0.774–0.783) for mPSAD, with p < 0.001. MRI-PMbdex showed net benefit over biopsy in all men when the probability of csPCa was greater than 2%, while mPSAD did the same when the probability of csPCa was greater than 18%. Thresholds of 13.5% for MRI-PMbdex and 0.628 ng/mL2 for mPSAD had 95% sensitivity for csPCa and presented 51.1% specificity for MRI-PMbdex and 19.6% specificity for mPSAD, with p < 0.001. MRI-PMbdex exhibited net benefit over mPSAD in men with prostate imaging report and data system (PI-RADS) <4, while neither exhibited any benefit in men with PI-RADS 5. Hence, we can conclude that MRI-PMbdex is more accurate than mPSAD for the proper selection of candidates for prostate biopsy among men with suspected PCa, with the exception of men with a PI-RAD S 5 score, for whom neither tool exhibited clinical guidance to determine the need for biopsy., This research was funded by Instituto de Salut Carlos III (ESP), grant number PI20/01666.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Sequencing the Barcelona-MRI predictive model and Proclarix for improving the uncertain PI-RADS 3

  • Mendez, Olga
  • Celma, Ana
  • Enrique, Trilla Herrera
  • Morote Robles, Juan
Proclarix; Prostate cancer; Screening, Proclarix; Cáncer de próstata; Cribado, Proclarix; Càncer de pròstata; Cribratge, The Instituto de Salut Carlos III (SP) and European Union financed this project, ref. PI20/01666.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Developing a Predictive Model for Significant Prostate Cancer Detection in Prostatic Biopsies from Seven Clinical Variables: Is Machine Learning Superior to Logistic Regression?

  • Hernando-Sánchez, Patricia
  • Morote Robles, Juan
  • Miro, Berta
  • Paesano, Nahuel
  • Picola Brau, Natalia
  • Muñoz-Rodriguez, Jesus
  • Celma, Ana
  • Enrique, Trilla Herrera
  • Mendez, Olga
Logistic regression; Predictive models; Prostate cancer detection, Regresión logística; Modelos predictivos; Detección de cáncer de próstata, Regressió logística; Models predictius; Detecció de càncer de pròstata, Objective: This study compares machine learning (ML) and logistic regression (LR) algorithms in developing a predictive model for sPCa using the seven predictive variables from the Barcelona (BCN-MRI) predictive model. Method: A cohort of 5005 men suspected of having PCa who underwent MRI and targeted and/or systematic biopsies was used for training, testing, and validation. A feedforward neural network (FNN)-based SimpleNet model (GMV) and a logistic regression-based model (BCN) were developed. The models were evaluated for discrimination ability, precision-recall, net benefit, and clinical utility. Both models demonstrated strong predictive performance. Results: The GMV model achieved an area under the curve of 0.88 in training and 0.85 in test cohorts (95% CI: 0.83-0.90), while the BCN model reached 0.85 and 0.84 (95% CI: 0.82-0.87), respectively (p > 0.05). The GMV model exhibited higher recall, making it more suitable for clinical scenarios prioritizing sensitivity, whereas the BCN model demonstrated higher precision and specificity, optimizing the reduction of unnecessary biopsies. Both models provided similar clinical benefit over biopsying all men, reducing unnecessary procedures by 27.5-29% and 27-27.5% of prostate biopsies at 95% sensitivity, respectively (p > 0.05). Conclusions: Our findings suggest that both ML and LR models offer high accuracy in sPCa detection, with ML exhibiting superior recall and LR optimizing specificity. These results highlight the need for model selection based on clinical priorities., This research was funded by the Ministerio de Asuntos Económicos y Transformación Digital (SP) (MIA.2021.M02.0005) and the Instituto de Salut Carlos III (SP) through the project “PI20/01666” (Co-funded by European Regional Development Fund “A way to make Europe”).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Validation of the Barcelona-MRI predictive model when PI-RADS v2.1 is used with transperineal prostate biopsies

  • Paesano, Nahuel
  • Picola Brau, Natalia
  • Muñoz-Rodriguez, Jesus
  • Ruiz Plazas, Xavier
  • Miro, Berta
  • Celma, Ana
  • Muñoz Rivero, Marta Viridiana
  • Morote Robles, Juan
Diagnosis; Magnetic resonance imaging; Prostatic neoplasms, Diagnòstic; Imatge de ressonància magnètica; Neoplàsies prostàtiques, Diagnóstico; Imagen por resonancia magnética; Neoplasias prostáticas, Purpose: To validate the Barcelona magnetic resonance imaging predictive model (BCN-MRI PM) in men with pre-biopsy multiparametric MRI (mpMRI) reported with the Prostate Imaging Reporting and Data System (PI-RADS) v2.1, followed by transrectal and transperineal prostate biopsies. Materials and Methods: Prospective analysis of 3,264 men with PSA >3.0 ng/mL and/or abnormal digital rectal examination who were referred to ten participant centers in the csPCa early detection program of Catalonia (Spain), between 2021 and 2023. MpMRI was reported with the PI-RADS v2.1, and 2- to 4-core MRI-transrectal ultrasound (TRUS) fusion-targeted biopsy of suspected lesions and/or 12-core systematic biopsy were conducted. 2,295 (70.3%) individuals were referred to six centers for transrectal prostate biopsies, while 969 (39.7%) were referred to four centers for transperineal prostate biopsies. CsPCa was classified whenever the International Society of Urologic Pathology grade group was 2 or higher. Results: CsPCa was detected in 41% of transrectal prostate biopsies and in 45.9% of transperineal prostate biopsies (p <0.016). Both BCN-MRI PM calibration curves were within the ideal correlation between predicted and observed csPCa. Areas under the curve and 95% confidence intervals were 0.847 (0.830-0.857) and 0.830 (0.823-0.855), respectively (p = 0.346). Specificities corresponding to 95% sensitivity were 37.6 and 36.8%, respectively (p = 0.387). The Net benefit of the BCN-MRI PM was similar with both biopsy methods. Conclusions: The BCN-MRI PM has been successfully validated when mpMRI was reported with the PI-RADS v2.1 and prostate biopsies were conducted via the transrectal and transperineal route., This study was funded by the Instituto de Salut Carlos III (SP) and the European Union (Grant number PI20/01666).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Barcelona Predictive Model of Clinically Significant Prostate Cancer

  • Morote Robles, Joan
  • Celma Domènech, Ana
  • Regis Plácido, Lucas
  • Escobar Amores, Manuel
  • Mast, Richard
  • Torres Ramirez, Inés de
  • Planas Morin, Jacques
  • Trilla Herrera, Enric
  • Triquell Llauradó, Marina
  • Borque Fernando, Ángel
  • Semidey Raven, Maria Eugenia
  • Santamaria Margalef, Anna
Clinically significant prostate cancer; Magnetic resonance imaging; Predictive model, Cáncer de próstata clínicamente significativo; Imagen de resonancia magnética; Modelo predictivo, Càncer de pròstata clínicament significatiu; Imatge per ressonància magnètica; Model predictiu, A new and externally validated MRI-PM for csPCa was developed in the metropolitan area of Barcelona, and a web-RC designed with the new option of selecting the csPCa probability threshold. The development cohort comprised 1486 men scheduled to undergo a 3-tesla multiparametric MRI (mpMRI) and guided and/or systematic biopsies in one academic institution of Barcelona. The external validation cohort comprised 946 men in whom the same diagnostic approach was carried out as in the development cohort, in two other academic institutions of the same metropolitan area. CsPCa was detected in 36.9% of men in the development cohort and 40.8% in the external validation cohort (p = 0.054). The area under the curve of mpMRI increased from 0.842 to 0.897 in the developed MRI-PM (p < 0.001), and from 0.743 to 0.858 in the external validation cohort (p < 0.001). A selected 15% threshold avoided 40.1% of prostate biopsies and missed 5.4% of the 36.9% csPCa detected in the development cohort. In men with PI-RADS <3, 4.3% would be biopsied and 32.3% of all existing 4.2% of csPCa would be detected. In men with PI-RADS 3, 62% of prostate biopsies would be avoided and 28% of all existing 12.4% of csPCa would be undetected. In men with PI-RADS 4, 4% of prostate biopsies would be avoided and 0.6% of all existing 43.1% of csPCa would be undetected. In men with PI-RADS 5, 0.6% of prostate biopsies would be avoided and none of the existing 42.0% of csPCa would be undetected. The Barcelona MRI-PM presented good performance on the overall population; however, its clinical usefulness varied regarding the PI-RADS category. The selection of csPCa probability thresholds in the designed RC may facilitate external validation and outperformance of MRI-PMs in specific PI-RADS categories., This research was funded by the Instituto de Salud Carlos III (ESP), grant number PI20/01666.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Role of Digital Rectal Examination for Early Detection of Significant Prostate Cancer in the Era of Magnetic Resonance Imaging

  • Mendez Fernández, Olga
  • Paesano, Nahuel
  • Picola Brau, Natalia
  • Muñoz-Rodriguez, Jesus
  • Ruiz Plazas, Xavier
  • Celma, Ana
  • Enrique, Trilla Herrera
  • Muñoz Rivero, Marta Viridiana
  • Morote Robles, Juan
Digital rectal examination; Early detection; Prostate cancer, Examen rectal digital; Detección precoz; Cáncer de próstata, Examen rectal digital; Detecció precoç; Càncer de pròstata, The role of digital rectal examination (DRE) in the early detection of significant prostate cancer (PCa) is being questioned in the era of magnetic resonance imaging (MRI). However, some men with suspected PCa may still be identified solely through DRE, even with low serum prostate-specific antigen (PSA) levels. Additionally, most predictive models designed to improve significant PCa diagnostic pathways incorporate DRE findings. We assessed the role of DRE among 5005 men with serum PSA levels > 3.0 ng/mL and/or suspicious DRE findings, who underwent pre-biopsy MRI and targeted and/or systematic biopsies, as part of the significant PCa opportunistic screening program in Catalonia (Spain) between 2016 and 2023. Significant PCa, defined as grade group > 2, was detected in 2097 men (41.9%). Suspicion of PCa was based solely on DRE in 206 cases (4.1%) with significant PCa detected in 50 of them (2.4%). Two pathways using the Barcelona predictive models, before and after MRI, with and without DRE findings showed specificities of 52.8 and 38.7%, respectively (p < 0.001), after fixing sensitivity at 90%. Prostate biopsy was avoided in 35.1 and 26.7%, respectively (p < 0.001), while its efficacy increased from 52.8 to 58%. We conclude that DRE improved the effectiveness of an opportunistic significant PCa-screening program., This research was funded by the Ministerio de Asuntos Económicos y Transformación Digital (SP) (MIA.2021.M02.0005) and the Instituto de Salut Carlos III (SP) (PI20/01666).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Role of Digital Rectal Examination Prostate Volume Category in the Early Detection of Prostate Cancer: Its Correlation with the Magnetic Resonance Imaging Prostate Volume

  • Muñoz-Rodriguez, Jesus
  • Miró Cau, Berta
  • Picola Brau, Natalia
  • Paesano, Nahuel
  • Ruiz Plazas, Xavier
  • Celma, Ana
  • Muñoz Rivero, Marta Viridiana
  • Morote Robles, Juan
Digital rectal examination; Magnetic resonance imaging; Prostate volume, Exploración rectal digital; Imagen por resonancia magnética; Volumen de próstata, Exploració rectal digital; Imatge per ressonància magnètica; Volum de pròstata, Purpose To relate the prostate volume category (PVC) assessed with digital rectal examination (DRE)—small, median, and large—and the prostate volumes (PVs) assessed with magnetic resonance imaging (MRI) and transrectal ultrasound (TRUS). To compare the clinically significant prostate cancer (csPCa) discrimination ability of two predictive models based on DRE-PVC and MRI-PV. Materials and Methods A prospective trial of 2,090 men with prostate-specific antigen >3 ng/mL and/or PCa suspicious DRE were prospectively recruited in 10 centers from Catalonia (Spain), between 2021 and 2022, in whom DRE-PVC was assessed. Pre-biopsy MRI, and 12-core TRUS-random biopsy was always performed after 2- to 6-core TRUS-fusion targeted biopsy of prostate imaging-report and data system >3 lesions. In 370 men (17.7%) the DRE-PVC was unconclusive. Among the 1,720 men finally analyzed the csPCa (grade group >2) detection was 42.4%. Results The median (interquartile range) of TRUS and MRI-PVs of small prostates were 33 mL (19–37 mL) and 35 mL (23–30 mL), p=0.410; in median prostates they were 51 mL (38–58 mL) and 55 mL (48–63 mL) respectively, p<0.001; in large prostates 80 mL (60–100 mL) and 95 mL (75–118 mL) respectively, p<0.001. The predictive models sharing the MRI-PV and DRE-PVC showed areas under the curves of 0.832 (95% confidence interval [CI], 0.813–0.851) and 0.828 (95% CI, 0.809–0.848) respectively, p=0.632, as well as similar net benefit and clinical utility. Conclusions PVC was unconclusive in 17% of DREs. MRI-PV overestimated the TRUS-PV in median and large prostates. The predictive models based on MRI-PV and DRE-PVC showed similar efficacy to predict csPCa. PVC assessed with DRE is helpful to predict the csPCa risk before MRI., The study is supported by the Instituto de Salut Carlos III (SP) and European Union (PI20/01666).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors

  • Esteban, Luis M.
  • Borque Fernando, Ángel
  • Picola Brau, Natalia
  • Muñoz-Rodriguez, Jesus
  • Paesano, Nahuel
  • Miro, Berta
  • Celma, Ana
  • Morote Robles, Juan
5-alpha reductase inhibitor; Predictive model; Prostate cancer, Inhibidor de la 5-alfa reductasa; Modelo predictivo; Cáncer de próstata, Inhibidor de la 5-alfa reductasa; Model predictiu; Càncer de pròstata, Purpose To validate the Barcelona-magnetic resonance imaging predictive model (BCN-MRI PM) for clinically significant prostate cancer (csPCa) in Catalonia, a Spanish region with 7.9 million inhabitants. Additionally, the BCN-MRI PM is validated in men receiving 5-alpha reductase inhibitors (5-ARI). Materials and methods A population of 2,212 men with prostate-specific antigen serum level > 3.0 ng/ml and/or a suspicious digital rectal examination who underwent multiparametric MRI and targeted and/or systematic biopsies in the year 2022, at ten participant centers of the Catalonian csPCa early detection program, were selected. 120 individuals (5.7%) were identified as receiving 5-ARI treatment for longer than a year. The risk of csPCa was retrospectively assessed with the Barcelona-risk calculator 2 (BCN-RC 2). Men undergoing 5-ARI treatment for less than a year were excluded. CsPCa was defined when the grade group was ≥ 2. Results The area under the curve of the BCN-MRI PM in 5-ARI naïve men was 0.824 (95% CI 0.783–0.842) and 0.849 (0.806–0.916) in those receiving 5-ARI treatment, p 0.475. Specificities at 100, 97.5, and 95% sensitivity thresholds were to 2.7, 29.3, and 39% in 5-ARI naïve men, while 43.5, 46.4, and 47.8%, respectively in 5-ARI users. The application of BCN-MRI PM would result in a reduction of 23.8% of prostate biopsies missing 5% of csPCa in 5-ARI naïve men, while reducing 25% of prostate biopsies without missing csPCa in 5-ARI users. Conclusions The BCN-MRI PM has achieved successful validation in Catalonia and, notably, for the first time, in men undergoing 5-ARI treatment., This research was supported by the Instituto de Salut Carlos III (SP) and the European Union (PI20/01666). Open Access Funding provided by Universitat Autonoma de Barcelona.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Need of Systematic Biopsies for the Appropriate Management of Localized Prostate Cancer

  • Catalá, Violeta
  • Paesano, Nahuel
  • Morote Robles, Juan
Systematic biopsies; Localized prostate cancer, Biòpsies sistemàtiques; Càncer de pròstata localitzat, Biopsias sistemáticas; Cáncer de próstata localizado, This study was supported by the Instituto de Salut Carlos III (SP) and the European Union (PI20/01666).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer

  • Campistol, Miriam
  • Mendez Fernández, Olga
  • Borque Fernando, Ángel
  • Triquell Llauradó, Marina
  • Servian, Pol
  • Abascal, Jose Maria
  • Planas, Jacques
  • Enrique, Trilla Herrera
  • Morote Robles, Juan
Magnetic resonance imaging; Prostate cancer; Risk calculator, Imatges per ressonància magnètica; Càncer de pròstata; Calculadora de riscos, Imágenes por resonancia magnética; Cáncer de próstata; Calculadora de riesgos, Background Magnetic resonance imaging (MRI)-based risk calculators (MRI-RCs) individualise the likelihood of clinically significant prostate cancer (csPCa) and improve candidate selection for prostate biopsy beyond the Prostate Imaging Reporting and Data System (PI-RADS). Objective To compare the Barcelona (BCN) and Rotterdam (ROT) MRI-RCs in an entire population and according to the PI-RADS categories. Design, setting, and participants A prospective comparison of BCN- and ROT-RC in 946 men with suspected prostate cancer in whom systematic biopsy was performed, as well as target biopsies of PI-RADS ≥3 lesions. Outcome measurements and statistical analysis Saved biopsies and undetected csPCa (grade group ≥2) were determined. Results and limitations The csPCa detection was 40.8%. The median risks of csPCa from BCN- and ROT-RC were, respectively, 67.1% and 25% in men with csPCa, whereas 10.5% and 3% in those without csPCa (p < 0.001). The areas under the curve were 0.856 and 0.844, respectively (p = 0.116). BCN-RC showed a higher net benefit and clinical utility over ROT-RC. Using appropriate thresholds, respectively, 75% and 80% of biopsies were needed to identify 50% of csPCa detected in men with PI-RADS <3, whereas 35% and 21% of biopsies were saved, missing 10% of csPCa detected in men with PI-RADS 3. BCN-RC saved 15% of biopsies, missing 2% of csPCa in men with PI-RADS 4, whereas ROT-RC saved 10%, missing 6%. No RC saved biopsies without missing csPCa in men with PI-RADS 5. Conclusions ROT-RC provided a lower and narrower range of csPCa probabilities than BCN-RC. BCN-RC showed a net benefit over ROT-RC in the entire population. However, BCN-RC was useful in men with PI-RADS 3 and 4, whereas ROT-RC was useful only in those with PI-RADS 3. No RC seemed to be helpful in men with negative MRI and PI-RADS 5., This study was supported by the Instituto Carlos III (SP) and the European Union (project ref: PI20/01666).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category

  • Morote Robles, Juan|||0000-0002-2168-323X
  • Campistol i Torres, Miriam|||0000-0002-3212-3473
  • Triquell, Marina|||0000-0003-3881-8177
  • Celma, Ana|||0000-0002-3128-3811
  • Regis, Lucas|||0000-0001-7121-1946
  • de Torres, Inés|||0000-0002-5495-9140
  • Semidey Raven, Maria Eugenia|||0000-0001-8539-9265
  • Mast, Richard|||0000-0001-6005-800X
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Planas Morin, Jacques|||0000-0002-0222-584X
  • Trilla Herrera, Enrique|||0000-0001-9401-0872
The efficacy of tools for selection of candidates for prostate biopsy after multiparametric magnetic resonance imaging (MRI) varies across Prostate Imaging-Reporting and Data System (PI-RADS) categories. The new Proclarix test performs better than prostate-specific antigen density and the European Randomized Study of Screening for Prostate Cancer MRI predictive model in the challenging PI-RADS 3 category. Proclarix guaranteed 100% detection of clinically significant prostate cancer (PCa), avoiding almost one-quarter of prostate biopsies and decreasing overdetection of insignificant PCa from 16.6% to 11.2%. Prostate Imaging-Reporting and Data System (PI-RADS) category 3 is a challenging scenario for detection of clinically significant prostate cancer (csPCa) and some tools can improve the selection of appropriate candidates for prostate biopsy. To assess the performance of the European Randomized Study of Screening for Prostate Cancer (ERSPC) magnetic resonance imaging (MRI) model, the new Proclarix test, and prostate-specific antigen density (PSAD) in selecting candidates for prostate biopsy among men in the PI-RADS 3 category. We conducted a head-to-head prospective analysis of 567 men suspected of having PCa for whom guided and systematic biopsies were scheduled between January 2018 and March 2020 in a single academic institution. A PI-RADS v.2 category 3 lesion was identified in 169 men (29.8%). csPCa, insignificant PCa (iPCa), and unnecessary biopsy rates were analysed. csPCa was defined as grade group ≥2. Receiver operating characteristic (ROC) curves, decision curve analysis curves, and clinical utility curves were plotted. PCa was detected in 53/169 men (31.4%) with a PI-RADS 3 lesion, identified as csPCa in 25 (14.8%) and iPCa in 28 (16.6%). The area under the ROC curve for csPCa detection was 0.703 (95% confidence interval [CI] 0.621-0.768) for Proclarix, 0.657 (95% CI 0.547-0.766) for the ERSPC MRI model, and 0.612 (95% CI 0.497-0.727) for PSAD (p = 0.027). The threshold with the highest sensitivity was 10% for Proclarix, 1.5% for the ERSPC MRI model, and 0.07 ng/ml/cm 3 for PSAD, which yielded sensitivity of 100%, 91%, and 84%, respectively. Some 21.3%, 26.2%, and 7.1% of biopsies would be avoided with Proclarix, PSAD, and the ERSPC MRI model, respectively. Proclarix showed a net benefit over PSAD and the ERSPC MRI model. Both Proclarix and PSAD reduced iPCa overdetection from 16.6% to 11.3%, while the ERSPC MRI model reduced iPCa overdetection to 15.4%. Proclarix was more accurate in selecting appropriate candidates for prostate biopsy among men in the PI-RADS 3 category when compared to PSAD and the ERSPC MRI model. Proclarix detected 100% of csPCa cases and would reduce prostate biopsies by 21.3% and iPCa overdetection by 5.3%. We compared three methods and found that the Proclarix test can optimise the detection of clinically significant prostate cancer in men with a score of 3 on the Prostate Imaging-Reporting and Data System for magnetic resonance imaging scans.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Multiparametric Magnetic Resonance Imaging Grades the Aggressiveness of Prostate Cancer

  • Morote Robles, Juan|||0000-0002-2168-323X
  • Borque-Fernando, Ángel|||0000-0003-0178-4567
  • Triquell, Marina|||0000-0003-3881-8177
  • Celma, Ana|||0000-0002-3128-3811
  • Regis, Lucas|||0000-0001-7121-1946
  • Mast, Richard|||0000-0001-6005-800X
  • de Torres, Inés|||0000-0002-5495-9140
  • Semidey Raven, Maria Eugenia|||0000-0001-8539-9265
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Planas Morin, Jacques|||0000-0002-0222-584X
  • Esteban, Luis M.|||0000-0002-3007-302X
  • Trilla Herrera, Enrique|||0000-0001-9401-0872
Prostate cancer (PCa) aggressiveness can be assessed from clinical and pathologic surrogate endpoints as the International Society of Uropathology grade group (GG) in prostate biopsies, the type of pathology from surgical specimens, the clinical stage, and the risk of biochemical recurrence after treatment of localised PCa. Low evidence exists about the association between prostate magnetic resonance imaging (MRI) and PCa aggressiveness beyond the known increased risk of clinically significant PCa (csPCa) as Prostate Imaging and Data Report System (PI-RADS) increase. Therefore, we confirm previous data and generate new evidence from all the previous surrogate endpoints of PCa aggressiveness, confirming that MRI grades the aggressiveness of PCa. We sought to find further evidence showing the increase in PCa aggressiveness as PI-RADS score increases from four surrogates of PCa aggressiveness: i. prostate biopsy GG (≤3 vs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Barcelona Predictive Model of Clinically Significant Prostate Cancer

  • Morote Robles, Juan|||0000-0002-2168-323X
  • Borque-Fernando, Ángel|||0000-0003-0178-4567
  • Triquell, Marina|||0000-0003-3881-8177
  • Celma, Ana|||0000-0002-3128-3811
  • Regis, Lucas|||0000-0001-7121-1946
  • Escobar, Manuel|||0000-0002-3794-2224
  • Mast, Richard|||0000-0001-6005-800X
  • de Torres, Inés|||0000-0002-5495-9140
  • Semidey Raven, Maria Eugenia|||0000-0001-8539-9265
  • Abascal, Jose Maria|||0000-0001-8374-6593
  • Solà Belda, Carles|||0000-0002-2646-0465
  • Servian, Pol|||0000-0002-3727-8159
  • Salvador Hidalgo, Daniel
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Planas Morin, Jacques|||0000-0002-0222-584X
  • Esteban, Luis M.|||0000-0002-3007-302X
  • Trilla Herrera, Enrique|||0000-0001-9401-0872
Magnetic-resonance-imaging-based predictive models (MRI-PMs) improve the MRI prediction of clinically significant prostate cancer (csPCa) in prostate biopsies. Risk calculators (RC) provide easy individual assessment of csPCa likelihood. MRI-PMs have been analysed in overall populations of men suspected to have PCa, but they have never been analysed according to the prostate imaging-report and data system (PI-RADS) categories. Therefore, the true clinical usefulness of MRI-PMs regarding the specific PI-RADS categories is unknown. A new and externally validated MRI-PM for csPCa was developed in the metropolitan area of Barcelona, and a web-RC designed with the new option of selecting the csPCa probability threshold. The development cohort comprised 1486 men scheduled to undergo a 3-tesla multiparametric MRI (mpMRI) and guided and/or systematic biopsies in one academic institution of Barcelona. The external validation cohort comprised 946 men in whom the same diagnostic approach was carried out as in the development cohort, in two other academic institutions of the same metropolitan area. CsPCa was detected in 36.9% of men in the development cohort and 40.8% in the external validation cohort (p = 0.054). The area under the curve of mpMRI increased from 0.842 to 0.897 in the developed MRI-PM (p < 0.001), and from 0.743 to 0.858 in the external validation cohort (p < 0.001). A selected 15% threshold avoided 40.1% of prostate biopsies and missed 5.4% of the 36.9% csPCa detected in the development cohort. In men with PI-RADS <3, 4.3% would be biopsied and 32.3% of all existing 4.2% of csPCa would be detected. In men with PI-RADS 3, 62% of prostate biopsies would be avoided and 28% of all existing 12.4% of csPCa would be undetected. In men with PI-RADS 4, 4% of prostate biopsies would be avoided and 0.6% of all existing 43.1% of csPCa would be undetected. In men with PI-RADS 5, 0.6% of prostate biopsies would be avoided and none of the existing 42.0% of csPCa would be undetected. The Barcelona MRI-PM presented good performance on the overall population; however, its clinical usefulness varied regarding the PI-RADS category. The selection of csPCa probability thresholds in the designed RC may facilitate external validation and outperformance of MRI-PMs in specific PI-RADS categories.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A risk-organised model for clinically significant prostate cancer early detection

  • Morote Robles, Juan|||0000-0002-2168-323X
  • Borque-Fernando, Ángel|||0000-0003-0178-4567
  • Triquell, Marina|||0000-0003-3881-8177
  • Abascal, Jose Maria|||0000-0001-8374-6593
  • Servian, Pol|||0000-0002-3727-8159
  • Planas Morin, Jacques|||0000-0002-0222-584X
  • Méndez Fernández, Olga|||0000-0003-4237-330X
  • Esteban, Luis M.|||0000-0002-3007-302X
  • Trilla Herrera, Enrique|||0000-0001-9401-0872
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer

  • Morote Robles, Juan|||0000-0002-2168-323X
  • Borque-Fernando, Ángel|||0000-0003-0178-4567
  • Triquell, Marina|||0000-0003-3881-8177
  • Campistol i Torres, Miriam|||0000-0002-3212-3473
  • Servian, Pol|||0000-0002-3727-8159
  • Abascal, Jose Maria|||0000-0001-8374-6593
  • Planas Morin, Jacques|||0000-0002-0222-584X
  • Méndez Fernández, Olga|||0000-0003-4237-330X
  • Esteban, Luis M.|||0000-0002-3007-302X
  • Trilla Herrera, Enrique|||0000-0001-9401-0872
The Barcelona magnetic resonance imaging (MRI)-based risk calculator (BCN MRI-RC) exhibited, in the analysed population, better behaviour than the Rotterdam-MRI risk calculator to improve candidate selection for prostate biopsy for the early detection of clinically significant prostate cancer. We note the importance of the discrimination, net benefit, and clinical utility analysis regarding Prostate Imaging Reporting and Data System (PI-RADS) categories. We summarise that both risk calculators were helpful in men with PI-RADS 3, only the BCN MRI-RC in those with PI-RADS 4, and none of these in men with negative MRI and PI-RADS 5. Magnetic resonance imaging (MRI)-based risk calculators (MRI-RCs) individualise the likelihood of clinically significant prostate cancer (csPCa) and improve candidate selection for prostate biopsy beyond the Prostate Imaging Reporting and Data System (PI-RADS). To compare the Barcelona (BCN) and Rotterdam (ROT) MRI-RCs in an entire population and according to the PI-RADS categories. A prospective comparison of BCN- and ROT-RC in 946 men with suspected prostate cancer in whom systematic biopsy was performed, as well as target biopsies of PI-RADS ≥3 lesions. Saved biopsies and undetected csPCa (grade group ≥2) were determined. The csPCa detection was 40.8%. The median risks of csPCa from BCN- and ROT-RC were, respectively, 67.1% and 25% in men with csPCa, whereas 10.5% and 3% in those without csPCa (p < 0.001). The areas under the curve were 0.856 and 0.844, respectively (p = 0.116). BCN-RC showed a higher net benefit and clinical utility over ROT-RC. Using appropriate thresholds, respectively, 75% and 80% of biopsies were needed to identify 50% of csPCa detected in men with PI-RADS <3, whereas 35% and 21% of biopsies were saved, missing 10% of csPCa detected in men with PI-RADS 3. BCN-RC saved 15% of biopsies, missing 2% of csPCa in men with PI-RADS 4, whereas ROT-RC saved 10%, missing 6%. No RC saved biopsies without missing csPCa in men with PI-RADS 5. ROT-RC provided a lower and narrower range of csPCa probabilities than BCN-RC. BCN-RC showed a net benefit over ROT-RC in the entire population. However, BCN-RC was useful in men with PI-RADS 3 and 4, whereas ROT-RC was useful only in those with PI-RADS 3. No RC seemed to be helpful in men with negative MRI and PI-RADS 5. Barcelona risk calculator was more helpful than Rotterdam risk calculator to select candidates for prostate biopsy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Clinically Significant Prostate Cancer Predictive Model Using Digital Rectal Examination Prostate Volume Category to Stratify Initial Prostate Cancer Suspicion and Reduce Magnetic Resonance Imaging Demand

  • Morote Robles, Juan|||0000-0002-2168-323X
  • Borque-Fernando, Ángel|||0000-0003-0178-4567
  • Triquell, Marina|||0000-0003-3881-8177
  • Campistol i Torres, Miriam|||0000-0002-3212-3473
  • Celma, Ana|||0000-0002-3128-3811
  • Regis, Lucas|||0000-0001-7121-1946
  • Abascal, Jose Maria|||0000-0001-8374-6593
  • Servian, Pol|||0000-0002-3727-8159
  • Planas Morin, Jacques|||0000-0002-0222-584X
  • Méndez Fernández, Olga|||0000-0003-4237-330X
  • Esteban, Luis M.|||0000-0002-3007-302X
  • Trilla Herrera, Enrique|||0000-0001-9401-0872
Early detection of PCa (PCa) has evolved towards clinically significant PCa (csPCa) after the spread of pre-biopsy multiparametric magnetic resonance imaging (mpMRI). However, PCa suspicion remains based on prostate-specific antigen (PSA) elevation and/or abnormal digital rectal examination (DRE). This change of paradigm and approach has reduced unnecessary prostate biopsies and overdetection of insignificant PCa, while the demand for mpMRI has skyrocketed despite its implementation not being allowed at all sites. The European Association of Urology (EAU) proposes risk-organized models for early detection of csPCa stratifying the initial PCa suspicion to reduce MRI scans and then prostate biopsies after mpMRI. Risk calculators are efficient tools for individualizing the risk of csPCa, especially when prostate volume is included in the predictive models. After the development and external validation of the Barcelona MRI risk calculator (BCN-RC 2) for the selection of candidates for prostate biopsy, we have now developed and externally validated BCN-RC 1 with the aim of reduce mpMRI demand. Both BCN-RC 1 and RC 2 are ready to be integrated in a risk-organized model for early detection of csPCa. A predictive model including age, PCa family history, biopsy status (initial vs repeat), DRE (normal vs abnormal), serum prostate-specific antigen (PSA), and DRE prostate volume ca-tegory was developed to stratify initial PCa suspicion in 1486 men with PSA.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy

  • Morote Robles, Juan|||0000-0002-2168-323X
  • Borque-Fernando, Ángel|||0000-0003-0178-4567
  • Triquell, Marina|||0000-0003-3881-8177
  • Celma, Ana|||0000-0002-3128-3811
  • Regis, Lucas|||0000-0001-7121-1946
  • Mast, Richard|||0000-0001-6005-800X
  • de Torres, Inés|||0000-0002-5495-9140
  • Semidey Raven, Maria Eugenia|||0000-0001-8539-9265
  • Abascal, Jose Maria|||0000-0001-8374-6593
  • Servian, Pol|||0000-0002-3727-8159
  • Fàbrega-Santamaria, Anna|||0000-0002-3866-2291
  • Planas Morin, Jacques|||0000-0002-0222-584X
  • Esteban, Luis M.|||0000-0002-3007-302X
  • Trilla Herrera, Enrique|||0000-0001-9401-0872
Magnetic resonance imaging (MRI)-associated prostate-specific antigen density (mPSAD) and MRI predictive models have been proposed for improving the selection of candidates for prostate biopsy among men with suspected prostate cancer (PCa). While the calculation of mPSAD only requires a simple division, the individual risk assessment of PCa using the available risk calculators is also a swift process. We aim to compare the clinical usefulness of mPSAD and an MRI predictive model that utilises the same predictors as the recently developed and externally validated Barcelona MRI predictive model (MRI-PMbdex). This study is a head-to-head comparison between mPSAD and MRI-PMbdex. The MRI-PMbdex was created from 2432 men with suspected PCa; this cohort comprised the development and external validation cohorts of the Barcelona MRI predictive model. Pre-biopsy 3-Tesla multiparametric MRI (mpMRI) and 2 to 4-core transrectal ultrasound (TRUS)-guided biopsies for suspicious lesions and/or 12-core TRUS systematic biopsies were scheduled. Clinically significant PCa (csPCa), defined as Gleason-based Grade Group 2 or higher, was detected in 934 men (38.4%). The area under the curve was 0.893 (95% confidence interval [CI]: 0.880-0.906) for MRI-PMbdex and 0.764 (95% CI: 0.774-0.783) for mPSAD, with p < 0.001. MRI-PMbdex showed net benefit over biopsy in all men when the probability of csPCa was greater than 2%, while mPSAD did the same when the probability of csPCa was greater than 18%. Thresholds of 13.5% for MRI-PMbdex and 0.628 ng/mL 2 for mPSAD had 95% sensitivity for csPCa and presented 51.1% specificity for MRI-PMbdex and 19.6% specificity for mPSAD, with p < 0.001. MRI-PMbdex exhibited net benefit over mPSAD in men with prostate imaging report and data system (PI-RADS) <4, while neither exhibited any benefit in men with PI-RADS 5. Hence, we can conclude that MRI-PMbdex is more accurate than mPSAD for the proper selection of candidates for prostate biopsy among men with suspected PCa, with the exception of men with a PI-RAD S 5 score, for whom neither tool exhibited clinical guidance to determine the need for biopsy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Diagnostic Accuracy Study of Targeted and Systematic Biopsies to Detect Clinically Significant Prostate Cancer, including a Model for the Partial Omission of Systematic Biopsies

  • Morote Robles, Juan|||0000-0002-2168-323X
  • Picola, Natàlia|||0000-0002-8944-4294
  • Muñoz Rodríguez, Jesús|||0000-0001-5406-4729
  • Paesano, Nahuel|||0000-0001-9278-5543
  • Ruiz-Plazas, Xavier|||0000-0003-2135-3860
  • Muñoz Rivero, Marta Viridiana|||0000-0002-6899-3956
  • Celma, Ana|||0000-0002-3128-3811
  • García-de Manuel, Gemma
  • Aisian, Ignacio
  • Servian, Pol|||0000-0002-3727-8159
  • Abascal, Jose Maria|||0000-0001-8374-6593
The primary objective of this study was to analyse the current accuracy of targeted and systematic prostate biopsies in detecting csPCa. A secondary objective was to determine whether there are factors predicting the finding of csPCa in targeted biopsies and, if so, to explore the utility of a predictive model for csPCa detection only in targeted biopsies. We analysed 2122 men with suspected PCa, serum PSA.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and Prostate Cancer Detection

  • Morote Robles, Juan|||0000-0002-2168-323X
  • Picola, Natàlia|||0000-0002-8944-4294
  • Muñoz Rodríguez, Jesús|||0000-0001-5406-4729
  • Paesano, Nahuel|||0000-0001-9278-5543
  • Ruiz-Plazas, Xavier|||0000-0003-2135-3860
  • Muñoz Rivero, Marta Viridiana|||0000-0002-6899-3956
  • Celma, Ana|||0000-0002-3128-3811
  • Manuel, Gemma García-de
  • Miró, Berta|||0000-0001-6049-8697
  • Servian, Pol|||0000-0002-3727-8159
  • Abascal, Jose Maria|||0000-0001-8374-6593
Concerns exist regarding the effects of 5-alpha reductase inhibitors (5-ARIs) on multipa-rametric magnetic resonance imaging (mpMRI) and clinically significant prostate cancer (csPCa) detection. Our objective is to analyze the effect of 5-ARI on the prostate imaging-reporting and data system (PI-RADS) distribution and csPCa and insignificant PCa (iPCa) detection. Among 2212 men with serum prostate-specific antigen levels of.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Role of Digital Rectal Examination Prostate Volume Category in the Early Detection of Prostate Cancer, Its Correlation with the Magnetic Resonance Imaging Prostate Volume

  • Morote Robles, Juan|||0000-0002-2168-323X
  • Picola, Natàlia|||0000-0002-8944-4294
  • Muñoz Rodríguez, Jesús|||0000-0001-5406-4729
  • Paesano, Nahuel|||0000-0001-9278-5543
  • Ruiz-Plazas, Xavier|||0000-0003-2135-3860
  • Muñoz Rivero, Marta Viridiana|||0000-0002-6899-3956
  • Celma, Ana|||0000-0002-3128-3811
  • García-de Manuel, Gemma
  • Miró, Berta|||0000-0001-6049-8697
  • Abascal, Jose Maria|||0000-0001-8374-6593
  • Servian, Pol|||0000-0002-3727-8159
To relate the prostate volume category (PVC) assessed with digital rectal examination (DRE)-small, median, and large-and the prostate volumes (PVs) assessed with magnetic resonance imaging (MRI) and transrectal ultrasound (TRUS). To compare the clinically significant prostate cancer (csPCa) discrimination ability of two predictive models based on DRE-PVC and MRI-PV. A prospective trial of 2,090 men with prostate-specific antigen.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The True Utility of Predictive Models Based on Magnetic Resonance Imaging in Selecting Candidates for Prostate Biopsy

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Evaluating the Quality of Local Programs for Early Detection of Significant Prostate Cancer

  • Morote Robles, Juan|||0000-0002-2168-323X
  • Paesano, Nahuel|||0000-0001-9278-5543
  • Picola, Natàlia|||0000-0002-8944-4294
  • Muñoz Rodríguez, José Manuel|||0000-0002-4688-6420
  • Ruiz-Plazas, Xavier|||0000-0003-2135-3860
  • Muñoz Rivero, Marta Viridiana|||0000-0002-6899-3956
  • Celma, Ana|||0000-0002-3128-3811
  • García-de Manuel, Gemma
  • Abascal, Jose Maria|||0000-0001-8374-6593
  • Servian, Pol|||0000-0002-3727-8159
Quality control of programs for detection of significant prostate cancer (sPCa) could be defined by the correlation between observed and reference 95% confidence intervals (CIs) for Prostate Imaging-Reporting and Data System (PI-RADS) categories. We used the area under the receiver operating characteristic curve (AUC) for the Barcelona magnetic resonance imaging (MRI) predictive model to screen the quality of ten participant centers in the sPCa opportunistic early detection program in Catalonia. We set an AUC of <0.8 as the criterion for suboptimal quality. Quality was confirmed in terms of the correlation between actual sPCa detection rates and reference 95% CIs. For a cohort of 2624 men with prostate-specific antigen.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors

  • Morote Robles, Juan|||0000-0002-2168-323X
  • Borque-Fernando, Ángel|||0000-0003-0178-4567
  • Esteban, Luis M.|||0000-0002-3007-302X
  • Picola, Natàlia|||0000-0002-8944-4294
  • Muñoz Rodríguez, Jesús|||0000-0001-5406-4729
  • Paesano, Nahuel|||0000-0001-9278-5543
  • Ruiz-Plazas, Xavier|||0000-0003-2135-3860
  • Muñoz Rivero, Marta Viridiana|||0000-0002-6899-3956
  • Celma, Ana|||0000-0002-3128-3811
  • García-de Manuel, Gemma
  • Miró, Berta|||0000-0001-6049-8697
  • Abascal, Jose Maria|||0000-0001-8374-6593
  • Servian, Pol|||0000-0002-3727-8159
Purpose: To validate the Barcelona-magnetic resonance imaging predictive model (BCN-MRI PM) for clinically significant prostate cancer (csPCa) in Catalonia, a Spanish region with 7.9 million inhabitants. Additionally, the BCN-MRI PM is validated in men receiving 5-alpha reductase inhibitors (5-ARI). Materials and methods: A population of 2,212 men with prostate-specific antigen serum level.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparing Two Targeted Biopsy Schemes for Detecting Clinically Significant Prostate Cancer in Magnetic Resonance Index Lesions, Two- to Four-Core versus Saturated Transperineal Targeted Biopsy

  • Morote Robles, Juan|||0000-0002-2168-323X
  • Paesano, Nahuel|||0000-0001-9278-5543
  • Picola, Natàlia|||0000-0002-8944-4294
  • Miró, Berta|||0000-0001-6049-8697
  • Abascal, Jose Maria|||0000-0001-8374-6593
  • Servian, Pol|||0000-0002-3727-8159
  • Trilla Herrera, Enrique|||0000-0001-9401-0872
  • Méndez Fernández, Olga|||0000-0003-4237-330X
Targeted biopsies of suspicious lesions detected in magnetic resonance imaging are crucial to discover clinically significant prostate cancer, especially those corresponding to index lesions. However, the optimal scheme for targeted biopsies remains unclear, despite the fact that a two- to four-core scheme is usually recommended. Saturated biopsies of the prostate gland have shown high efficiency in detecting significant PCa. In this article, we report a better efficacy for mapping using a 0.5 mm core biopsy scheme than that using the two- to four-core scheme for detecting clinically significant prostate cancer in magnetic resonance index lesions. Since the optimal scheme for targeted biopsies of magnetic resonance imaging (MRI) suspicious lesions remains unclear, we compare the efficacy of two schemes for these index lesions. A prospective trial was conducted in 1161 men with Prostate Imaging Reporting and Data System v 2.1 3-5 undergoing targeted and 12-core systematic biopsy in four centers between 2021 and 2023. Two- to four-core MRI-transrectal ultrasound fusion-targeted biopsies via the transperineal route were conducted in 900 men in three centers, while a mapping per 0.5 mm core method (saturated scheme) was employed in 261 men biopsied in another center. A propensity-matched 261 paired cases were selected for avoiding confounders other than the targeted biopsy scheme. CsPCa (grade group ≥ 2) was identified in 125 index lesions (41.1%) when the two- to four-core scheme was employed, while in 187 (71.9%) when the saturated biopsy (p < 0.001) was used. Insignificant PCa (iPCa) was detected in 18 and 11.1%, respectively (p = 0.019). Rates of csPCa and iPCa remained similar in systematic biopsies. CsPCa detected only in systematic biopsies were 5 and 1.5%, respectively (p = 0.035) in each group. The saturated scheme for targeted biopsies detected more csPCa and less iPCa than did the two- to four-core scheme in the index lesions. The rate of csPCa detected only in the systematic biopsies decreased when the saturated scheme was employed.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Validation of the Barcelona-MRI predictive model when PI-RADS v2.1 is used with transperineal prostate biopsies

  • Paesano, Nahuel
  • Picola Brau, Natalia
  • Muñoz-Rodriguez, Jesus
  • Ruiz Plazas, Xavier
  • Miro, Berta
  • Celma, Ana
  • Muñoz Rivero, Marta Viridiana
  • Morote Robles, Juan
Diagnosis; Magnetic resonance imaging; Prostatic neoplasms, Diagnòstic; Imatge de ressonància magnètica; Neoplàsies prostàtiques, Diagnóstico; Imagen por resonancia magnética; Neoplasias prostáticas, Purpose: To validate the Barcelona magnetic resonance imaging predictive model (BCN-MRI PM) in men with pre-biopsy multiparametric MRI (mpMRI) reported with the Prostate Imaging Reporting and Data System (PI-RADS) v2.1, followed by transrectal and transperineal prostate biopsies. Materials and Methods: Prospective analysis of 3,264 men with PSA >3.0 ng/mL and/or abnormal digital rectal examination who were referred to ten participant centers in the csPCa early detection program of Catalonia (Spain), between 2021 and 2023. MpMRI was reported with the PI-RADS v2.1, and 2- to 4-core MRI-transrectal ultrasound (TRUS) fusion-targeted biopsy of suspected lesions and/or 12-core systematic biopsy were conducted. 2,295 (70.3%) individuals were referred to six centers for transrectal prostate biopsies, while 969 (39.7%) were referred to four centers for transperineal prostate biopsies. CsPCa was classified whenever the International Society of Urologic Pathology grade group was 2 or higher. Results: CsPCa was detected in 41% of transrectal prostate biopsies and in 45.9% of transperineal prostate biopsies (p <0.016). Both BCN-MRI PM calibration curves were within the ideal correlation between predicted and observed csPCa. Areas under the curve and 95% confidence intervals were 0.847 (0.830-0.857) and 0.830 (0.823-0.855), respectively (p = 0.346). Specificities corresponding to 95% sensitivity were 37.6 and 36.8%, respectively (p = 0.387). The Net benefit of the BCN-MRI PM was similar with both biopsy methods. Conclusions: The BCN-MRI PM has been successfully validated when mpMRI was reported with the PI-RADS v2.1 and prostate biopsies were conducted via the transrectal and transperineal route., This study was funded by the Instituto de Salut Carlos III (SP) and the European Union (Grant number PI20/01666).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The Role of Digital Rectal Examination for Early Detection of Significant Prostate Cancer in the Era of Magnetic Resonance Imaging

  • Mendez Fernández, Olga
  • Paesano, Nahuel
  • Picola Brau, Natalia
  • Muñoz-Rodriguez, Jesus
  • Ruiz Plazas, Xavier
  • Celma, Ana
  • Enrique, Trilla Herrera
  • Muñoz Rivero, Marta Viridiana
  • Morote Robles, Juan
Digital rectal examination; Early detection; Prostate cancer, Examen rectal digital; Detección precoz; Cáncer de próstata, Examen rectal digital; Detecció precoç; Càncer de pròstata, The role of digital rectal examination (DRE) in the early detection of significant prostate cancer (PCa) is being questioned in the era of magnetic resonance imaging (MRI). However, some men with suspected PCa may still be identified solely through DRE, even with low serum prostate-specific antigen (PSA) levels. Additionally, most predictive models designed to improve significant PCa diagnostic pathways incorporate DRE findings. We assessed the role of DRE among 5005 men with serum PSA levels > 3.0 ng/mL and/or suspicious DRE findings, who underwent pre-biopsy MRI and targeted and/or systematic biopsies, as part of the significant PCa opportunistic screening program in Catalonia (Spain) between 2016 and 2023. Significant PCa, defined as grade group > 2, was detected in 2097 men (41.9%). Suspicion of PCa was based solely on DRE in 206 cases (4.1%) with significant PCa detected in 50 of them (2.4%). Two pathways using the Barcelona predictive models, before and after MRI, with and without DRE findings showed specificities of 52.8 and 38.7%, respectively (p < 0.001), after fixing sensitivity at 90%. Prostate biopsy was avoided in 35.1 and 26.7%, respectively (p < 0.001), while its efficacy increased from 52.8 to 58%. We conclude that DRE improved the effectiveness of an opportunistic significant PCa-screening program., This research was funded by the Ministerio de Asuntos Económicos y Transformación Digital (SP) (MIA.2021.M02.0005) and the Instituto de Salut Carlos III (SP) (PI20/01666).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Comparing Two Targeted Biopsy Schemes for Detecting Clinically Significant Prostate Cancer in Magnetic Resonance Index Lesions: Two- to Four-Core versus Saturated Transperineal Targeted Biopsy

  • Mendez Fernández, Olga
  • Paesano, Nahuel
  • Picola Brau, Natalia
  • Miro, Berta
  • Abascal, Jose Maria
  • Servian, Pol
  • Enrique, Trilla Herrera
  • Morote Robles, Juan
Number of cores; Prostate cancer; Targeted biopsy, Número de núcleos; Cáncer de próstata; Biopsia dirigida, Nombre de nuclis; Càncer de pròstata; Biòpsia dirigida, Since the optimal scheme for targeted biopsies of magnetic resonance imaging (MRI) suspicious lesions remains unclear, we compare the efficacy of two schemes for these index lesions. A prospective trial was conducted in 1161 men with Prostate Imaging Reporting and Data System v 2.1 3–5 undergoing targeted and 12-core systematic biopsy in four centers between 2021 and 2023. Two- to four-core MRI-transrectal ultrasound fusion-targeted biopsies via the transperineal route were conducted in 900 men in three centers, while a mapping per 0.5 mm core method (saturated scheme) was employed in 261 men biopsied in another center. A propensity-matched 261 paired cases were selected for avoiding confounders other than the targeted biopsy scheme. CsPCa (grade group ≥ 2) was identified in 125 index lesions (41.1%) when the two- to four-core scheme was employed, while in 187 (71.9%) when the saturated biopsy (p < 0.001) was used. Insignificant PCa (iPCa) was detected in 18 and 11.1%, respectively (p = 0.019). Rates of csPCa and iPCa remained similar in systematic biopsies. CsPCa detected only in systematic biopsies were 5 and 1.5%, respectively (p = 0.035) in each group. The saturated scheme for targeted biopsies detected more csPCa and less iPCa than did the two- to four-core scheme in the index lesions. The rate of csPCa detected only in the systematic biopsies decreased when the saturated scheme was employed., This research was funded by the Ministerio de Asuntos Económicos y Transformación Digital (SP) (MIA.2021.M02.0005) and the Instituto de Salut Carlos III (SP) (PI20/01666).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The Barcelona Predictive Model of Clinically Significant Prostate Cancer

  • Morote Robles, Joan
  • Celma Domènech, Ana
  • Regis Plácido, Lucas
  • Escobar Amores, Manuel
  • Mast, Richard
  • Torres Ramirez, Inés de
  • Planas Morin, Jacques
  • Trilla Herrera, Enric
  • Triquell Llauradó, Marina
  • Borque Fernando, Ángel
  • Semidey Raven, Maria Eugenia
  • Santamaria Margalef, Anna
Clinically significant prostate cancer; Magnetic resonance imaging; Predictive model, Cáncer de próstata clínicamente significativo; Imagen de resonancia magnética; Modelo predictivo, Càncer de pròstata clínicament significatiu; Imatge per ressonància magnètica; Model predictiu, A new and externally validated MRI-PM for csPCa was developed in the metropolitan area of Barcelona, and a web-RC designed with the new option of selecting the csPCa probability threshold. The development cohort comprised 1486 men scheduled to undergo a 3-tesla multiparametric MRI (mpMRI) and guided and/or systematic biopsies in one academic institution of Barcelona. The external validation cohort comprised 946 men in whom the same diagnostic approach was carried out as in the development cohort, in two other academic institutions of the same metropolitan area. CsPCa was detected in 36.9% of men in the development cohort and 40.8% in the external validation cohort (p = 0.054). The area under the curve of mpMRI increased from 0.842 to 0.897 in the developed MRI-PM (p < 0.001), and from 0.743 to 0.858 in the external validation cohort (p < 0.001). A selected 15% threshold avoided 40.1% of prostate biopsies and missed 5.4% of the 36.9% csPCa detected in the development cohort. In men with PI-RADS <3, 4.3% would be biopsied and 32.3% of all existing 4.2% of csPCa would be detected. In men with PI-RADS 3, 62% of prostate biopsies would be avoided and 28% of all existing 12.4% of csPCa would be undetected. In men with PI-RADS 4, 4% of prostate biopsies would be avoided and 0.6% of all existing 43.1% of csPCa would be undetected. In men with PI-RADS 5, 0.6% of prostate biopsies would be avoided and none of the existing 42.0% of csPCa would be undetected. The Barcelona MRI-PM presented good performance on the overall population; however, its clinical usefulness varied regarding the PI-RADS category. The selection of csPCa probability thresholds in the designed RC may facilitate external validation and outperformance of MRI-PMs in specific PI-RADS categories., This research was funded by the Instituto de Salud Carlos III (ESP), grant number PI20/01666.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and Prostate Cancer Detection

  • Celma Domènech, Ana
  • Picola Brau, Natalia
  • Paesano, Nahuel
  • Ruiz Plazas, Xavier
  • Miro, Berta
  • Muñoz-Rodriguez, Jesus
  • Muñoz Rivero, Marta Viridiana
  • Morote Robles, Juan
Biopsy; Prostate cancer; Screening, Biòpsia; Càncer de pròstata; Cribratge, Biopsia; Cáncer de próstata; Cribado, Concerns exist regarding the effects of 5-alpha reductase inhibitors (5-ARIs) on multipa-rametric magnetic resonance imaging (mpMRI) and clinically significant prostate cancer (csPCa) detection. Our objective is to analyze the effect of 5-ARI on the prostate imaging–reporting and data system (PI-RADS) distribution and csPCa and insignificant PCa (iPCa) detection. Among 2212 men with serum prostate-specific antigen levels of >3.0 ng/mL and/or suspicious digital rectal examinations who underwent mpMRI and targeted and/or systematic biopsies, 120 individuals exposed to 5-ARI treatment for over a year were identified. CsPCa was defined when the grade group (GG) was >2. The overall csPCa and iPCa detection rates were 44.6% and 18.8%, respectively. Since logistic regression revealed independent predictors of PCa, a randomized matched group of 236 individuals was selected for analysis. The PI-RADS distribution was comparable with 5-ARI exposure (p 0.685). The CsPCa detection rates in 5-ARI-naïve men and 5-ARI-exposed men were 52.6% and 47.4%, respectively (p 0.596). IPCa was detected in 37.6 and 62.5%, respectively (p 0.089). The tumor GG distribution based on 5-ARI exposure was similar (p 0.149) to the rates of csPCa and iPCa across the PI-RADS categories. We conclude that exposure to 5-ARI in suspected PCa men did not change the PI-RADS distribution and the csPCa and iPCa detection rates., This research was funded by the Instituto de Salut Carlos III (SP) and the European Union (PI20/01666).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors

  • Esteban, Luis M.
  • Borque Fernando, Ángel
  • Picola Brau, Natalia
  • Muñoz-Rodriguez, Jesus
  • Paesano, Nahuel
  • Miro, Berta
  • Celma, Ana
  • Morote Robles, Juan
5-alpha reductase inhibitor; Predictive model; Prostate cancer, Inhibidor de la 5-alfa reductasa; Modelo predictivo; Cáncer de próstata, Inhibidor de la 5-alfa reductasa; Model predictiu; Càncer de pròstata, Purpose To validate the Barcelona-magnetic resonance imaging predictive model (BCN-MRI PM) for clinically significant prostate cancer (csPCa) in Catalonia, a Spanish region with 7.9 million inhabitants. Additionally, the BCN-MRI PM is validated in men receiving 5-alpha reductase inhibitors (5-ARI). Materials and methods A population of 2,212 men with prostate-specific antigen serum level > 3.0 ng/ml and/or a suspicious digital rectal examination who underwent multiparametric MRI and targeted and/or systematic biopsies in the year 2022, at ten participant centers of the Catalonian csPCa early detection program, were selected. 120 individuals (5.7%) were identified as receiving 5-ARI treatment for longer than a year. The risk of csPCa was retrospectively assessed with the Barcelona-risk calculator 2 (BCN-RC 2). Men undergoing 5-ARI treatment for less than a year were excluded. CsPCa was defined when the grade group was ≥ 2. Results The area under the curve of the BCN-MRI PM in 5-ARI naïve men was 0.824 (95% CI 0.783–0.842) and 0.849 (0.806–0.916) in those receiving 5-ARI treatment, p 0.475. Specificities at 100, 97.5, and 95% sensitivity thresholds were to 2.7, 29.3, and 39% in 5-ARI naïve men, while 43.5, 46.4, and 47.8%, respectively in 5-ARI users. The application of BCN-MRI PM would result in a reduction of 23.8% of prostate biopsies missing 5% of csPCa in 5-ARI naïve men, while reducing 25% of prostate biopsies without missing csPCa in 5-ARI users. Conclusions The BCN-MRI PM has achieved successful validation in Catalonia and, notably, for the first time, in men undergoing 5-ARI treatment., This research was supported by the Instituto de Salut Carlos III (SP) and the European Union (PI20/01666). Open Access Funding provided by Universitat Autonoma de Barcelona.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer

  • Campistol, Miriam
  • Mendez Fernández, Olga
  • Borque Fernando, Ángel
  • Triquell Llauradó, Marina
  • Servian, Pol
  • Abascal, Jose Maria
  • Planas, Jacques
  • Enrique, Trilla Herrera
  • Morote Robles, Juan
Magnetic resonance imaging; Prostate cancer; Risk calculator, Imatges per ressonància magnètica; Càncer de pròstata; Calculadora de riscos, Imágenes por resonancia magnética; Cáncer de próstata; Calculadora de riesgos, Background Magnetic resonance imaging (MRI)-based risk calculators (MRI-RCs) individualise the likelihood of clinically significant prostate cancer (csPCa) and improve candidate selection for prostate biopsy beyond the Prostate Imaging Reporting and Data System (PI-RADS). Objective To compare the Barcelona (BCN) and Rotterdam (ROT) MRI-RCs in an entire population and according to the PI-RADS categories. Design, setting, and participants A prospective comparison of BCN- and ROT-RC in 946 men with suspected prostate cancer in whom systematic biopsy was performed, as well as target biopsies of PI-RADS ≥3 lesions. Outcome measurements and statistical analysis Saved biopsies and undetected csPCa (grade group ≥2) were determined. Results and limitations The csPCa detection was 40.8%. The median risks of csPCa from BCN- and ROT-RC were, respectively, 67.1% and 25% in men with csPCa, whereas 10.5% and 3% in those without csPCa (p < 0.001). The areas under the curve were 0.856 and 0.844, respectively (p = 0.116). BCN-RC showed a higher net benefit and clinical utility over ROT-RC. Using appropriate thresholds, respectively, 75% and 80% of biopsies were needed to identify 50% of csPCa detected in men with PI-RADS <3, whereas 35% and 21% of biopsies were saved, missing 10% of csPCa detected in men with PI-RADS 3. BCN-RC saved 15% of biopsies, missing 2% of csPCa in men with PI-RADS 4, whereas ROT-RC saved 10%, missing 6%. No RC saved biopsies without missing csPCa in men with PI-RADS 5. Conclusions ROT-RC provided a lower and narrower range of csPCa probabilities than BCN-RC. BCN-RC showed a net benefit over ROT-RC in the entire population. However, BCN-RC was useful in men with PI-RADS 3 and 4, whereas ROT-RC was useful only in those with PI-RADS 3. No RC seemed to be helpful in men with negative MRI and PI-RADS 5., This study was supported by the Instituto Carlos III (SP) and the European Union (project ref: PI20/01666).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Efficacy of Prostate Biopsies via Transperineal and Transrectal Routes for Significant Prostate Cancer Detection: A Multicenter Paired–Matched Study

  • Paesano, Nahuel
  • Picola Brau, Natalia
  • Muñoz-Rodriguez, Jesus
  • Ruiz Plazas, Xavier
  • Muñoz Rivero, Marta Viridiana
  • Celma, Ana
  • Miro, Berta
  • Enrique, Trilla Herrera
  • Morote Robles, Juan
Prostate biopsy; Prostate cancer; Transperineal, Biòpsia de pròstata; Càncer de pròstata; Transperineal, Biopsia de próstata; Cáncer de próstata; Transperineal, Background: A transperineal approach to prostate biopsy is now recommended to reduce the risk of infectious complications associated with the transrectal route. Our aim is to compare the efficacy of transrectal- and transperineal-guided biopsies involving the magnetic resonance imaging (MRI) of index lesions in detecting significant prostate cancer (sPCas), and to evaluate the role of systematic biopsies. Methods: In a prospective and multicenter trial conducted in an opportunistic early detection program for sPCa in Catalonia (Spain), between 2021 and 2023, 4029 men suspected of having PCa underwent multiparametric MRI followed by guided and systematic biopsies. From this cohort, we retrospectively selected 1376 men with reports of the size and localization of their index lesions. A matched group of 325 pairs of men subjected to transrectal and transperineal biopsy were chosen to account for confounding variables. We compared sPCa detection rates determined via index lesions and systematic biopsies, as well as by lesion localization. Results: Transperineal and transrectal biopsies detected sPCa in 49.5% vs. 40.6% overall (p = 0.027), 44.6% vs. 30.8% from index lesions (p = 0.001), and 24.3% vs. 35.1% from systematic biopsies (p = 0.003). SPCa detection rates were higher in transperineal biopsies across all index lesion localizations, with significant increases in the anterior zone (47.8% vs. 20.8% at the mid-base, p = 0.039, and 52.9% vs. 24.2% at the apex, p = 0.024) and central zone (33.3% vs. 5.9%, p = 0.003). With regards to SPCa detected only in systematic biopsies, 10.5% of cases were detected in transrectal biopsies and 4.9% of cases were detected in transperineal biopsies (p = 0.012). Conclusions: Targeted biopsies conducted via the transperineal route showed higher sPCa detection rates than transrectal biopsies, particularly for anterior and apical lesions, with systematic biopsies showing reduced utility., This research was supported by the Instituto de Salut Carlos III (SP) and the European Union (PI20/01666).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Magnetic Resonance Imaging-Based Predictive Models for Clinically Significant Prostate Cancer: A Systematic Review

  • Celma Domènech, Ana
  • Regis Plácido, Lucas
  • Planas Morin, Jacques
  • Trilla Herrera, Enric
  • Morote Robles, Joan
  • Triquell Llauradó, Marina
  • Campistol, Miriam
  • Cuadras Solé, Mercè
Magnetic resonance imaging; Predictive model; Prostate cancer, Imatges per ressonància magnètica; Model predictiu; Càncer de pròstata, Imágenes por resonancia magnética; Modelo predictivo; Cáncer de próstata, MRI can identify suspicious lesions, providing the semi-quantitative risk of csPCa through the Prostate Imaging-Report and Data System (PI-RADS). Predictive models of clinical variables that individualise the risk of csPCa have been developed by adding PI-RADS score (MRI-PMs). Our objective is to analyse the current developed MRI-PMs and define their clinical usefulness. A systematic review was performed after a literature search performed by two independent investigators in PubMed, Cochrane, and Web of Science databases, with the Medical Subjects Headings (MESH): predictive model, nomogram, risk model, magnetic resonance imaging, PI-RADS, prostate cancer, and prostate biopsy. This review was made following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) criteria and studied eligibility based on the Participants, Intervention, Comparator, and Outcomes (PICO) strategy. Among 723 initial identified registers, 18 studies were finally selected. Warp analysis of selected studies was performed with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. Clinical predictors in addition to the PI-RADS score in developed MRI-PMs were age, PCa family history, digital rectal examination, biopsy status (initial vs. repeat), ethnicity, serum PSA, prostate volume measured by MRI, or calculated PSA density. All MRI-PMs improved the prediction of csPCa made by clinical predictors or imaging alone and achieved most areas under the curve between 0.78 and 0.92. Among 18 developed MRI-PMs, 7 had any external validation, and two RCs were available. The updated PI-RADS version 2 was exclusively used in 11 MRI-PMs. The performance of MRI-PMs according to PI-RADS was only analysed in a single study. We conclude that MRI-PMs improve the selection of candidates for prostate biopsy beyond the PI-RADS category. However, few developed MRI-PMs meet the appropriate requirements in routine clinical practice., This research was funded by the Instituto de Salud Carlos III (ESP), grant number PI20/01666.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Investigating Efficient Risk-Stratified Pathways for the Early Detection of Clinically Significant Prostate Cancer

  • Esteban, Luis M.
  • Mendez Fernández, Olga
  • Borque Fernando, Ángel
  • Campistol, Miriam
  • Miro, Berta
  • Enrique, Trilla Herrera
  • Celma, Ana
  • Morote Robles, Juan
Prostate cancer; Risk-stratified pathway; Screening, Càncer de pròstata; Via estratificada de risc; Cribratge, Cáncer de próstata; Vía estratificada del riesgo; Cribado, Risk-stratified pathways (RSPs) are recommended by the European Association of Uro-logy (EAU) to improve the early detection of clinically significant prostate cancer (csPCa). RSPs can reduce magnetic resonance imaging (MRI) demand, prostate biopsies, and the over-detection of insignificant PCa (iPCa). Our goal is to analyze the efficacy and cost-effectiveness of several RSPs by using sequential stratifications from the serum prostate-specific antigen level and digital rectal examination, the Barcelona risk calculators (BCN-RCs), MRI, and Proclarix™. In a cohort of 567 men with a serum PSA level above 3.0 ng/mL who underwent multiparametric MRI (mpMRI) and targeted and/or systematic biopsies, the risk of csPCa was retrospectively assessed using Proclarix™ and BCN-RCs 1 and 2. Six RSPs were compared with those recommended by the EAU that, stratifying men from MRI, avoided 16.7% of prostate biopsies with a prostate imaging–reporting and data system score of <3, with 2.6% of csPCa cases remaining undetected. The most effective RSP avoided mpMRI exams in men with a serum PSA level of >10 ng/mL and suspicious DRE, following stratifications from BCN-RC 1, mpMRI, and Proclarix™. The demand for mpMRI decreased by 19.9%, prostate biopsies by 19.8%, and over-detection of iPCa by 22.7%, while 2.6% of csPCa remained undetected as in the recommended RSP. Cost-effectiveness remained when the Proclarix™ price was assumed to be below EUR 200., This research was funded by the Instituto de Salut Carlos III and the European Union, grant number PI20/01666.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Multiparametric Magnetic Resonance Imaging Grades the Aggressiveness of Prostate Cancer

  • Morote Robles, Joan
  • Celma Domènech, Ana
  • Regis Plácido, Lucas
  • Mast, Richard
  • Torres Ramirez, Inés de
  • Planas Morin, Jacques
  • Esteban, Luis M.
  • Trilla Herrera, Enric
  • Triquell Llauradó, Marina
  • Borque Fernando, Ángel
  • Semidey Raven, Maria Eugenia
  • Santamaria Margalef, Anna
Aggressiveness; Magnetic resonance imaging; Prostate cancer, Agresividad; Imágenes por resonancia magnética; Cáncer de próstata, Agressivitat; Imatges per ressonància magnètica; Càncer de pròstata, We sought to find further evidence showing the increase in PCa aggressiveness as PI-RADS score increases from four surrogates of PCa aggressiveness: i. prostate biopsy GG (≤3 vs. >3), ii. type of pathology in surgical specimens (favourable vs. unfavourable), iii. clinical stage (localised vs. advanced), and risk of recurrence of localised PCa after primary treatment (low-intermediate vs. high). A group of 692 PCa patients were diagnosed after 3-T multiparametric MRI (mpMRI) and guided and/or systematic biopsies, showing csPCa (GG ≥ 2) in 547 patients (79%) and insignificant PCa (iPCa) in 145 (21%). The csPCa rate increased from 32.4% in PI-RADS < 3 to 95.5% in PI-RADS 5 (p < 0.001). GG ≥ 3 was observed in 7.6% of PCa with PI-RADS < 3 and 32.6% in those with PI-RADS > 3 (p < 0.001). Unfavourable pathology was observed in 38.9% of PCa with PI-RAD < 3 and 68.3% in those with PI-RADS > 3 (p = 0.030). Advanced disease was not observed in PCa with PI-RADS ≤ 3, while it existed in 12.7% of those with PI-RADS > 3 (p < 0.001). High-risk recurrence localised PCa was observed in 9.5% of PCa with PI-RADS < 3 and 35% in those with PI-RADS > 3 (p = 0.001). The PI-RADS score was an independent predictor of all surrogates of PCa aggressiveness as PSA density. We confirmed that mpMRI grades PCa aggressiveness., This research was funded by Instituto de Salut Carlos III (ES) grant number PI20/01666.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Developing a Predictive Model for Significant Prostate Cancer Detection in Prostatic Biopsies from Seven Clinical Variables: Is Machine Learning Superior to Logistic Regression?

  • Hernando-Sánchez, Patricia
  • Morote Robles, Juan
  • Miro, Berta
  • Paesano, Nahuel
  • Picola Brau, Natalia
  • Muñoz-Rodriguez, Jesus
  • Celma, Ana
  • Enrique, Trilla Herrera
  • Mendez, Olga
Logistic regression; Predictive models; Prostate cancer detection, Regresión logística; Modelos predictivos; Detección de cáncer de próstata, Regressió logística; Models predictius; Detecció de càncer de pròstata, Objective: This study compares machine learning (ML) and logistic regression (LR) algorithms in developing a predictive model for sPCa using the seven predictive variables from the Barcelona (BCN-MRI) predictive model. Method: A cohort of 5005 men suspected of having PCa who underwent MRI and targeted and/or systematic biopsies was used for training, testing, and validation. A feedforward neural network (FNN)-based SimpleNet model (GMV) and a logistic regression-based model (BCN) were developed. The models were evaluated for discrimination ability, precision-recall, net benefit, and clinical utility. Both models demonstrated strong predictive performance. Results: The GMV model achieved an area under the curve of 0.88 in training and 0.85 in test cohorts (95% CI: 0.83-0.90), while the BCN model reached 0.85 and 0.84 (95% CI: 0.82-0.87), respectively (p > 0.05). The GMV model exhibited higher recall, making it more suitable for clinical scenarios prioritizing sensitivity, whereas the BCN model demonstrated higher precision and specificity, optimizing the reduction of unnecessary biopsies. Both models provided similar clinical benefit over biopsying all men, reducing unnecessary procedures by 27.5-29% and 27-27.5% of prostate biopsies at 95% sensitivity, respectively (p > 0.05). Conclusions: Our findings suggest that both ML and LR models offer high accuracy in sPCa detection, with ML exhibiting superior recall and LR optimizing specificity. These results highlight the need for model selection based on clinical priorities., This research was funded by the Ministerio de Asuntos Económicos y Transformación Digital (SP) (MIA.2021.M02.0005) and the Instituto de Salut Carlos III (SP) through the project “PI20/01666” (Co-funded by European Regional Development Fund “A way to make Europe”).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The Need of Systematic Biopsies for the Appropriate Management of Localized Prostate Cancer

  • Catalá, Violeta
  • Paesano, Nahuel
  • Morote Robles, Juan
Systematic biopsies; Localized prostate cancer, Biòpsies sistemàtiques; Càncer de pròstata localitzat, Biopsias sistemáticas; Cáncer de próstata localizado, This study was supported by the Instituto de Salut Carlos III (SP) and the European Union (PI20/01666).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Who with suspected prostate cancer can benefit from Proclarix after multiparametric magnetic resonance imaging?

  • Morote Robles, Joan
  • Regis Plácido, Lucas
  • Celma Domènech, Ana
  • Torres Ramirez, Inés de
  • Roche, Sarai
  • Mast, Richard
  • Planas Morin, Jacques
  • Trilla Herrera, Enric
  • Campistol, Miriam
  • Semidey Raven, Maria Eugenia
  • Santamaria Margalef, Anna
Cathepsin D; Magnetic resonance imaging; Proclarix, Catepsina D; Imatges per ressonància magnètica; Proclarix, Catepsina D; Imágenes por resonancia magnética; Proclarix, Proclarix is a new blood-based test to assess the likelihood of clinically significant prostate cancer (csPCa) defined as >2 grade group. In this study, we analyzed whether Proclarix and PSA density (PSAD) could improve the selection of candidates for prostate biopsy after multiparametric magnetic resonance imaging (mpMRI). Proclarix and PSAD were assessed in 567 consecutive men with suspected PCa in whom pre-biopsy 3 Tesla mpMRI, scoring with Prostate Imaging-Report and Data System (PI-RADS) v.2, and guided and/or systematic biopsies were performed. Proclarix and PSAD thresholds having csPCa sensitivity over 90% were found at 10% and 0.07 ng/(mL*cm3), respectively. Among 100 men with negative mpMRI (PI-RADS <3), csPCa was detected in 6 cases, which would have been undetected if systematic biopsies were avoided. However, Proclarix suggested performing a biopsy on 70% of men with negative mpMRI. In contrast, PSAD only detected 50% of csPCa and required 71% of prostate biopsies. In 169 men with PI-RADS 3, Proclarix avoided 21.3% of prostate biopsies and detected all 25 cases of csPCa, while PSAD avoided 26.3% of biopsies, but missed 16% of csPCa. In 190 men with PI-RADS 4 and 108 with PI-RADS 5, Proclarix avoided 12.1% and 5.6% of prostate biopsies, but missed 4.8% and 1% of csPCa, respectively. PSAD avoided 18.4% and 9.3% of biopsies, but missed 11.4% and 4.2% csPCa, respectively. We conclude that Proclarix outperformed PSAD in the selection of candidates for prostate biopsy, especially in men with PI-RADS <3., The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Instituto de Salud Carlos III, (grant number PI20/01666).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A Clinically Significant Prostate Cancer Predictive Model Using Digital Rectal Examination Prostate Volume Category to Stratify Initial Prostate Cancer Suspicion and Reduce Magnetic Resonance Imaging Demand

  • Morote Robles, Joan
  • Celma Domènech, Ana
  • Regis Plácido, Lucas
  • Planas Morin, Jacques
  • Mendez Fernández, Olga
  • Trilla Herrera, Enric
  • Triquell Llauradó, Marina
  • Borque Fernando, Ángel
  • Campistol, Miriam
Magnetic resonance imaging; Predictive model; Prostate cancer, Imágenes por resonancia magnética; Modelo predictivo; Cáncer de próstata, Imatges per ressonància magnètica; Model predictiu; Càncer de pròstata, A predictive model including age, PCa family history, biopsy status (initial vs repeat), DRE (normal vs abnormal), serum prostate-specific antigen (PSA), and DRE prostate volume ca-tegory was developed to stratify initial PCa suspicion in 1486 men with PSA > 3 ng/mL and/or abnormal DRE, in whom mpMRI followed; 2- to 4-core TRUS-guided biopsies where Prostate Imaging Report and Data System (PI-RADS) > 3 lesions and/or 12-core TRUS systematic biopsies were performed in one academic institution between 1 January 2016–31 December 2019. The csPCa detection rate, defined as International Society of Uro-Pathology grade group 2 or higher, was 36.9%. An external validation of designed BCN-RC 1 was carried out on 946 men from two other institutions in the same metropolitan area, using the same criteria of PCa suspicion and diagnostic approach, yielded a csPCa detection rate of 40.8%. The areas under the receiver operating characteristic curves of BCN-RC 1 were 0.823 (95% CI: 0.800–0.846) in the development cohort and 0.837 (95% CI: 0.811–0.863) in the validation cohort (p = 0.447). In both cohorts, BCN-RC 1 exhibited net benefit over performing mpMRI in all men from 8 and 12% risk thresholds, respectively. At 0.95 sensitivity of csPCa, the specificities of BCN-RC 1 were 0.24 (95% CI: 0.22–0.26) in the development cohort and 0.34 (95% CI: 0.31–0.37) in the validation cohort (p < 0.001). The percentages of avoided mpMRI scans were 17.2% in the development cohort and 22.3% in the validation cohort, missing between 1.8% and 2% of csPCa among men at risk of PCa. In summary, BCN-RC 1 can stratify initial PCa suspicion, reducing the demand of mpMRI, with an acceptable loss of csPCa., This research was funded by Instituto de Salut Carlos III (SP) and European Union, grant number PI20/01666.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The Role of Digital Rectal Examination Prostate Volume Category in the Early Detection of Prostate Cancer: Its Correlation with the Magnetic Resonance Imaging Prostate Volume

  • Muñoz-Rodriguez, Jesus
  • Miró Cau, Berta
  • Picola Brau, Natalia
  • Paesano, Nahuel
  • Ruiz Plazas, Xavier
  • Celma, Ana
  • Muñoz Rivero, Marta Viridiana
  • Morote Robles, Juan
Digital rectal examination; Magnetic resonance imaging; Prostate volume, Exploración rectal digital; Imagen por resonancia magnética; Volumen de próstata, Exploració rectal digital; Imatge per ressonància magnètica; Volum de pròstata, Purpose To relate the prostate volume category (PVC) assessed with digital rectal examination (DRE)—small, median, and large—and the prostate volumes (PVs) assessed with magnetic resonance imaging (MRI) and transrectal ultrasound (TRUS). To compare the clinically significant prostate cancer (csPCa) discrimination ability of two predictive models based on DRE-PVC and MRI-PV. Materials and Methods A prospective trial of 2,090 men with prostate-specific antigen >3 ng/mL and/or PCa suspicious DRE were prospectively recruited in 10 centers from Catalonia (Spain), between 2021 and 2022, in whom DRE-PVC was assessed. Pre-biopsy MRI, and 12-core TRUS-random biopsy was always performed after 2- to 6-core TRUS-fusion targeted biopsy of prostate imaging-report and data system >3 lesions. In 370 men (17.7%) the DRE-PVC was unconclusive. Among the 1,720 men finally analyzed the csPCa (grade group >2) detection was 42.4%. Results The median (interquartile range) of TRUS and MRI-PVs of small prostates were 33 mL (19–37 mL) and 35 mL (23–30 mL), p=0.410; in median prostates they were 51 mL (38–58 mL) and 55 mL (48–63 mL) respectively, p<0.001; in large prostates 80 mL (60–100 mL) and 95 mL (75–118 mL) respectively, p<0.001. The predictive models sharing the MRI-PV and DRE-PVC showed areas under the curves of 0.832 (95% confidence interval [CI], 0.813–0.851) and 0.828 (95% CI, 0.809–0.848) respectively, p=0.632, as well as similar net benefit and clinical utility. Conclusions PVC was unconclusive in 17% of DREs. MRI-PV overestimated the TRUS-PV in median and large prostates. The predictive models based on MRI-PV and DRE-PVC showed similar efficacy to predict csPCa. PVC assessed with DRE is helpful to predict the csPCa risk before MRI., The study is supported by the Instituto de Salut Carlos III (SP) and European Union (PI20/01666).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy

  • Morote Robles, Joan
  • Celma Domènech, Ana
  • Regis Plácido, Lucas
  • Mast, Richard
  • Torres Ramirez, Inés de
  • Planas Morin, Jacques
  • Trilla Herrera, Enric
  • Triquell Llauradó, Marina
  • Borque Fernando, Ángel
  • Semidey Raven, Maria Eugenia
  • Santamaria Margalef, Anna
Clinically significant prostate cancer; Predictive model; Prostate-specific antigen, Càncer de pròstata clínicament significatiu; Model predictiu; Antigen específic de la pròstata, Cáncer de próstata clínicamente significativo; Modelo predictivo; Antígeno específico de la próstata, This study is a head-to-head comparison between mPSAD and MRI-PMbdex. The MRI-PMbdex was created from 2432 men with suspected PCa; this cohort comprised the development and external validation cohorts of the Barcelona MRI predictive model. Pre-biopsy 3-Tesla multiparametric MRI (mpMRI) and 2 to 4-core transrectal ultrasound (TRUS)-guided biopsies for suspicious lesions and/or 12-core TRUS systematic biopsies were scheduled. Clinically significant PCa (csPCa), defined as Gleason-based Grade Group 2 or higher, was detected in 934 men (38.4%). The area under the curve was 0.893 (95% confidence interval [CI]: 0.880–0.906) for MRI-PMbdex and 0.764 (95% CI: 0.774–0.783) for mPSAD, with p < 0.001. MRI-PMbdex showed net benefit over biopsy in all men when the probability of csPCa was greater than 2%, while mPSAD did the same when the probability of csPCa was greater than 18%. Thresholds of 13.5% for MRI-PMbdex and 0.628 ng/mL2 for mPSAD had 95% sensitivity for csPCa and presented 51.1% specificity for MRI-PMbdex and 19.6% specificity for mPSAD, with p < 0.001. MRI-PMbdex exhibited net benefit over mPSAD in men with prostate imaging report and data system (PI-RADS) <4, while neither exhibited any benefit in men with PI-RADS 5. Hence, we can conclude that MRI-PMbdex is more accurate than mPSAD for the proper selection of candidates for prostate biopsy among men with suspected PCa, with the exception of men with a PI-RAD S 5 score, for whom neither tool exhibited clinical guidance to determine the need for biopsy., This research was funded by Instituto de Salut Carlos III (ESP), grant number PI20/01666.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Sequencing the Barcelona-MRI predictive model and Proclarix for improving the uncertain PI-RADS 3

  • Mendez, Olga
  • Celma, Ana
  • Enrique, Trilla Herrera
  • Morote Robles, Juan
Proclarix; Prostate cancer; Screening, Proclarix; Cáncer de próstata; Cribado, Proclarix; Càncer de pròstata; Cribratge, The Instituto de Salut Carlos III (SP) and European Union financed this project, ref. PI20/01666.